FMRP-Regulated Alternative Splicing is Multifactorial and Resembles Splicing Control by MBNL1

Suna Jung[1¶], Sneha Shah[1¶], Geongoo Han[2], and Joel D. Richter[1*]

[1] Program in Molecular Medicine

University of Massachusetts Chan Medical School

Worcester, Massachusetts, United States of America

[2] Molecular Microbiology and Immunology

Brown University

Providence, Rhode Island, United States of America

*corresponding author

Email: joel.richter@umassmed.edu

[¶]These authors contributed equally to this work.

Abstract

Fragile X Syndrome (FXS) is a neurodevelopmental disorder that is often modeled in *Fmr1* knockout mice where the RNA binding protein FMRP is absent. Here we show that in *Fmr1*-deficient mice, RNA mis-splicing occurs in several brain regions and peripheral tissues. To assess molecular mechanisms of splicing mis-regulation, we employed N2A cells depleted of *Fmr1*. In the absence of FMRP, RNA-specific exon skipping events are linked to the splicing factors hnRNPF, PTBP1, and MBNL1. FMRP regulates the translation of *Mbnl1* mRNA as well as *Mbnl1* RNA auto-splicing. Elevated *Mbnl1* auto-splicing in FMRP-deficient cells results in the loss of a nuclear localization signal (NLS)-containing exon. This in turn alters the nucleus-to-cytoplasm ratio of MBNL1. This re-distribution of MBNL1 isoforms in *Fmr1*-deficient cells could result in downstream splicing changes in other RNAs. Indeed, further investigation revealed that splicing distruptions resulting from *Fmr1* depletion could be rescued by overexpression of nuclear MBNL1. Altered *Mbnl1* auto-splicing also occurs in human FXS post-mortem brain. These data suggest that FMRP-controlled translation and RNA processing may cascade into a general dys-regulation of splicing in *Fmr1*-deficient cells.

Introduction

Fragile X Syndrome (FXS) is a neuro-developmental disorder characterized by mild to severe intellectual disability, speech and developmental delays, social impairment, perseveration, aggression, anxiety, and other maladies. FXS lies on the autism spectrum and is the most common single gene cause of autism. FXS is caused by an expansion of 200 or more CGG triplets in the 5' untranslated region (UTR) of *FMR1*, which in turn induces DNA methylation and gene silencing. Loss of the *FMR1* gene product FMRP results in the disruption of neuronal circuitry and synaptic efficacy, which produces an array of neuro-pathological conditions [1-3]. FMRP, an RNA binding protein present in probably all cells is frequently studied in mouse hippocampus, where several studies show that it represses protein synthesis [4-7]. This observation, in conjunction with results showing that FMRP co-sediments with polysomes in sucrose gradients [8, 9] and that in UV CLIPs (crosslink-immunoprecipitation) mostly to coding regions of mRNA [5, 10-12] suggests that it inhibits translation by impeding ribosome translocation. Indeed, it is now clear that at least one activity of FMRP is to stall ribosomes [5, 7, 13-15]. How this occurs is unclear, but it could involve codon bias or optimality [16, 17], impairment of ribosome function [18], or formation of translationally quiescent subcellular granules [13].

One group of FMRP target RNAs encodes chromatin modifying enzymes [5, 19, 20]. The synthesis of several of these enzymes is inhibited by FMRP; in its absence, excessive levels of these chromatin proteins alter the epigenetic landscape, which in turn impairs cognitive function [19]. A few mRNAs encoding epigenetic factors associate with FMRP-stalled ribosomes [15]. One of these, *Setd2*, encodes an enzyme that establishes the histone modification H3K36me3, which is most often located in gene bodies [21, 22]. In *Fmr1*-deficient mouse brain, SETD2 protein levels are elevated, which in turn alter the distribution of H3K36me3 chromatin marks. H3K36me3 has

been linked to alternative pre-mRNA splicing [23-25], and indeed there is some correlation between the genes with recast H3K36me3 and altered splicing in *Fmr1*-deficient mouse hippocampus [15]. The observation that *Fmr1*-deficiency results in hundreds of mis-splicing events prompted us to investigate both the prevalence and mechanism of FMRP-regulated nuclear pre-RNA processing.

We find that mis-splicing, mostly exon skipping, is widespread in *Fmr1*-deficient mice and occurs in all brain regions and peripheral tissues examined. To determine how FMRP might regulate splicing, we depleted *Fmr1* from mouse N2A cells, which resulted in hundreds of mis-splicing events. We focused on specific exons in three RNAs that are aberrantly skipped or included in *Fmr1*-deficient cells and mapped surrounding splicing factor consensus binding sites. Splicing factors MBNL1, PTBP1, and hnRNPF are responsible for altered splicing in *Fmr1*-deficient cells. FMRP regulates the translation of two factors, MBNL1 and hnRNPQ. Moreover, *Mbnl1* RNA itself undergoes alternative splicing, which is impaired in *Fmr1*-deficient cells. In the absence of FMRP, an NLS-containing exon is frequently skipped, which alters the nucleus-cytoplasm distribution of MBNL1. This change in subcellular localization of MBNL1 may affect splicing decisions on other mRNAs. Notably, AS events affected by FMRP and MBNL1 exhibit a robust correlation, and the ectopic expression of an MBNLl1 isoform containing an NLS rescues approximately one-fifth of the disrupted splicing in *Fmr1*-depleted cells. In addition, *Mbnl1* splicing is altered in human FXS post-mortem cortex, suggesting that it could modify the brain proteome and thereby contribute to intellectual impairment and Fragile X Syndrome.

Results

RNA splicing mis-regulation in *Fmr1* KO brain

Gene expression and RNA splicing are mis-regulated in the *Fmr1*-deficient mouse hippocampus [15] and FXS patient derived blood samples [26]. To determine whether this mis-regulation occurs in other brain regions and in peripheral tissues from mice, we sequenced RNA from (n=3, 2-3 month old) WT and *Fmr1* KO hippocampus, cerebellum, and cortex, as well as liver, muscle, and testis (**Fig 1A**). Volcano plots show that hundreds of RNAs are up or down-regulated in *Fmr1* KO cortex although fewer RNAs were similarly mis-regulated in hippocampus and cerebellum (log_2FC > 0.2 or < -0.2, FDR < 0.05, n=3) (**Fig 1B**). A Venn diagram shows that a significant group of RNAs, mostly encoding proteins involved in synapse or cell junction formation, was shared between hippocampus and cortex (**Fig 1C**). In the cortex, many upregulated RNAs encode proteins involved in RNA processing for biogenesis, while down regulated RNAs code for proteins mediating membrane potential and synapse organization (**Fig 1D**). Analysis of these RNA seq datasets demonstrates that hundreds of RNAs are mis-spliced, mostly exon skipping, in the *Fmr1*-deficient hippocampus, cortex, and cerebellum (p-value < 0.05, delta percent spliced-in [|delta PSI|] > 0.05, n=3) (**Fig 1E**). For the hippocampus and cortex, the percent of exons spliced in has a median of about 20% **Fig 1F**)**.** In the cortex and hippocampus, RNAs displaying differential exon skipping between the two genotypes encode proteins involved in synapse organization and development and JNK signaling, respectively (**Fig 1 and S1A**). **Fig 1G** shows RT-PCR confirmation of exon 6 skipping of Defective in Cullin Neddylation 1d2 (*Dcun1d2*) RNA. In both brain regions there was a > 2-fold increase in exon 6 skipping upon *Fmr1* deficiency compared to wild type (WT). Similar levels of the *Dcun1d2* constitutive exon 2 served as an internal control suggesting no change in *Dcun1d2* total RNA levels in the *Fmr1* KO tissues.

Figure 1. Differential gene expression in *Fmr1*-deficient brain and peripheral tissues.

(A) Schematic of experiment. Created with BioRender.com.

(B) Volcano plots of differential gene expression comparing WT and *Fmr1*-deficient cortex (CTX), hippocampus (HC), and cerebellum (CB). The numbers refer to those RNAs that are up or down-regulated between the two genotypes (n=3, FDR < 0.05).

(**C)** Venn diagram comparing differential RNA levels from WT and *Fmr1* KO HC, CTX, and CB (hypergeometric test, ***p < 0.001). GO terms for cellular components and adjust p-value for overlapped RNAs are indicated.

(D) GO terms for RNAs that are significantly up or down regulated in the CTX.

(E) Changes in alternative RNA splicing (SE, skipped exons; MXE, mutually exclusive exons; A3SS, alternative 3' splice site; A5SS, alternative 5' splice site; RI, retained intron) in *Fmr1* KO HC, CTX, or CB relative to WT (p < 0.05, n=3).

(F) Delta percent spliced in (delta PSI) distribution for HC and CTX. The solid line is the median and the dashed lines are quartiles. P-value < 0.05, |delta PSI| > 0.05.

(G) RT-PCR validation of altered *Dcun1d2* exon 6 inclusion/skipping in *Fmr1* KO HC and CTX. *Dcun1d2* constitutive Exon 2 was amplified to compare total mRNA levels between the genotypes and mean ± S.D is shown (Student's t-test, *p < 0.05, **p < 0.01).

(H) Changes in alternative RNA splicing events (SE, skipped exons; MXE, mutually exclusive exons; A3SS, alternative 3' splice site; A5SS, alternative 5' splice site; RI, retained intron) in *Fmr1* KO liver (LV), muscle (MU), and testis (TE) relative to WT (|delta PSI| > 0.05, p < 0.05, n=3).

(I) Comparison of all exon skipping changes in *Fmr1* brain regions and peripheral tissues relative to WT (hypergeometric test, *p < 0.05; **p < 0.01; ***p < 0.001).

Aberrant RNA splicing in *Fmr1* KO peripheral tissues

Because FMRP is expressed in probably all tissues, we examined RNA splicing in WT and *Fmr1* deficient liver, muscle (gastrocnemius), and testis. As with the brain, hundreds of RNAs are up or down regulated in FMRP KO peripheral tissues relative to WT (FDR, $p < 0.05$, n=3) (**Fig 1, S1B**), which may be somewhat surprising because relative *Fmr1* levels (in transcripts per million, TPM) in these tissues are about one-tenth the amount in the brain (**S1C**). In the liver, RNAs that are up or down regulated in FMRP KO relative to WT encode factors involved in various metabolic processes and catabolic and phosphorylation events, respectively (**S1D**). In muscle, up or down regulated RNAs encode factors involved in extra cellular matrix organization and mitochondrial function, respectively (**S1E**). In testis, up or down regulated RNAs encode factors involved in cell division, and reproductive system development, respectively (**S1F**).

In FMRP KO peripheral tissues, splicing mis-regulation is widespread; in the brain there are mostly skipped exons but many mutually exclusive exons as well ($p < 0.05$, $|\text{delta PSI}| > 0.05$, n=3) (**Fig 1H**). In the liver and muscle, RNAs with differential exon skipping between the two genotypes encode chromatin modifying enzymes and Wnt signaling components, respectively (**S1G**). Comparison of the RNAs from all brain regions and peripheral tissues that display significantly different exon skipping between the two genotypes shows a remarkable degree of overlap (**Fig 1I**). For example, nearly 20% of RNAs with skipped exons in hippocampus are the same as in cortex, which might be expected. However, ~10% of RNAs with skipped exons in the liver also exhibit exon skipping in the hippocampus. In this same vein, ~9% of RNAs with skipped exons in the testis also show exon skipping in the cortex. These data indicate that if FMRP regulates exon skipping in one type of tissue (e.g., the brain), it is likely to do so in another tissue (e.g., liver).

FMRP-regulated splicing in N2A cells

To investigate the mechanism of FMRP-mediated splicing, we surmised that using a single cell type approach would be more efficacious compared to a tissue containing multiple cell types. Consequently, we used mouse N2A neuroblastoma cells depleted of *Fmr1* by an siRNA complementary to this RNA's 3'UTR, which reduced FMRP levels by > 95% compared to a nontargeting (NT) control (**Fig 2A**). We next performed RNA-seq from cells transfected with either the nontargeting or *Fmr1* targeting siRNAs. **Fig 2B** and **S2A** shows that there were ~2000 RNAs that were mis-spliced ($p < 0.05$, |delta PSI| > 0.05). Several of these mis-splicing events were validated by RT-PCR: *Mapt* (microtubule associated protein tau) exon 4, *Tnik* (TRAF2 and NCK interacting kinase*)* exon 21, and *Wnk1* (WNK Lysine Deficient Protein Kinase 1) exon 11 were all included more in *Fmr1* depleted cells compared to nondepleted cells while *App* (amyloid precursor protein) exon 8, *Ski* (SKI protooncogene) exon 2, and *Os9* (Osteosarcoma Amplified 9, endoplasmic reticulum lectin) exon 13 were all skipped in *Fmr1*-depleted cells relative to non-depleted cells (**Fig 2C**).

Fig 2. Mis-regulated splicing in *Fmr1*-deficient mouse N2A neuroblastoma cells.

(A) Western blots showing depletion of FMRP following siRNA knockdown of *Fmr1*. GAPDH serves as a loading control. siNT refers to a nontargeting siRNA control.

(B) Types of mis-splicing events and the number of genes affected in *Fmr1*-depleted N2A cells ($p < 0.05$, |delta PSI| > 0.05;; n=2 for siNT, n=3 for siFmr1).

(C) qPCR validation of mis-splicing events (exons skipped or included) in six RNAs in *Fmr1*-depleted cells compared to siNT control (Student's t-test, n=3: *$p < 0.05$; **$p < 0.01$). Mean ± S.D is shown. Delta PSI and p-value of selected RNAs are shown in the table.

(D) CRISPR/Cas9-edited portion of *Fmr1***,** which deletes seven nucleotides leading to a frame-shift and nonsense-mediated RNA decay.

(**E)** Western blot of FMRP in control and *Fmr1*-edited cells.

(F) qPCR of *Mapt* exon 4 skipping/inclusion in *Fmr1*-edited cells compared to control and mean ± S.D is shown (Student's t-test, ****$p < 0.0001$).

(G) pFlare system for assessing exon skipping and inclusion. *Mapt* exon 4 was inserted into pFlareA. When the exon is skipped, GFP is expressed; when the exon is included, RFP is expressed. This plasmid, as well as an empty pcDNA plasmid or one that expresses mouse FMRP, was transfected into control or *Fmr1* KO N2A cells. The cells were then analyzed by flow cytometry. Created with BioRender.com.

(H) pFlare splicing reporter assay. Mean fluorescence intensity (MFI) of mCherry/GFP was evaluated by flow cytometry in both control and *Fmr1* KO CRISPR cell lines. At right, *Fmr1* KO CRISPR cell line was transfected with a splicing reporter that has a deletion of the MBNL1 binding site (UGCUGC) nearest to *Mapt* exon 4 (highlighted in red in the illustration). Western blot of FMRP from control cells, CRISP/Cas9-edited cells transduced with empty pcDNA, and CRISPR/Cas9-edited cells transduced with pcDNA FMRP. The histogram quantifies the ratio of cells expressing GFP or mCherry and mean ± S.D is shown (one-way ANOVA, **$p < 0.05$, n=3).

Rescue of mis-regulated splicing by FMRP replacement

To confirm FMRP control of splicing by an entirely different method, we used CRISPR/Cas9 gene editing to delete 7 nucleotides from exon 3 of *Fmr1*, which causes a reading frame shift to a stop codon resulting in nonsense mediated mRNA decay (**Fig 2D; S2B**) and a complete loss of FMRP (**Fig 2E**). In these KO cells, loss of *Mapt* exon 4 skipping was nearly identical as observed with siFmr1 knockdown of *Fmr1* (**Fig 2F**). We next generated a reporter construct where *Mapt* exon 4 and its flanking intron sequences were inserted into the pFlareA plasmid, which contains GFP and RFP sequences. Here, if *Mapt* exon 4 is skipped, an A nucleotide will generate a start codon when juxtaposed to a TG dinucleotide following splicing to the GFP reading frame and will express

GFP. If Mapt exon 4 is included, RFP will be expressed. This plasmid, together with an FMRP-expressing plasmid or an empty control plasmid, were transfected into normal or *Fmr1* KO N2A cells and green/red fluorescence intensity was analyzed by flow cytometry (**Fig 2G**). The quantification of Mean Fluorescence Intensity (MFI) for both mCherry and GFP was conducted through flow cytometry analysis in both the control and *Fmr1* KO cells (**Fig 2H**). As depicted in Figure 2H, the inclusion of *Mapt* exon 4 was elevated in the KO in comparison to the control. Interestingly, this inclusion was reversed upon the introduction of an FMRP overexpression plasmid. Moreover, the targeted deletion of a specific MBNL1 binding site, situated near exon 4, exhibited a reduction in *Mapt* exon 4 inclusion within the *Fmr1* KO cells. Intriguingly, this binding site deletion showed no discernible effect on the control cells (**S2C**). The western blot shows the expression level of FMRP relative to GAPDH. The "rescuing" ectopic FMRP was expressed at ~10% of endogenous FMRP levels. In the FMRP KO cells, *Mapt* exon 4 in the reporter was more included relative to that observed in control cells, which replicates the data with endogenous *Mapt* exon 4 with both siFmr1 depletion (**Fig 2C**) and CRISPR/Cas9-edited *Fmr1* KO cells (**Fig 2F**), albeit not to the same extent. Importantly, ectopic expression of FMRP in the KO cells restored *Mapt* exon 4 inclusion to control cells levels, demonstrating the reversibility of the exon skipping that is FMRP-dependent.

FMRP regulation of splicing factor activity

To identify splicing factors that might be regulated by FMRP, we focused on exons in three RNAs that are skipped or included in *Fmr1*-deficient cells and used the SFMap database [27] to identify potential splicing factor binding sites. *Mapt* exon 4, which is more included in *Fmr1*-deficient cells relative to control cells, is flanked by binding sites for splicing factors MBNL1, PTBP1, hnRNPF, and hnRNPQ (**Fig 3A**). We depleted the RNAs encoding each of these splicing factors as well as *Fmr1* (**S3A-H**). Depletion of *Mbnl1* resulted inclusion of exon 4 even more so compared to *Fmr1*

depletion. A double depletion of both *Mbnl1* and *Fmr1* caused even greater exon inclusion than the single depletions (**Fig 3B**). Constitutive *Mapt4* exon 15 was unaffected by these depletions (**S3I**). Depletion of *Ptbp1* also resulted in a greater inclusion of *Mapt* exon 4 than *Fmr1* depletion. A double *Fmr1/Ptbp1* depletion was similar to *Fmr1* depletion alone (**Fig 3B; S3J**). Depletion of hnRNPF or hnRNPQ had no effect on *Mapt* exon 4 skipping/inclusion (**Fig 3B; S3K,L**). Because the magnitude of *Mapt* exon 4 inclusion was additive when both *Mbnl1* and *Fmr1* were depleted, we surmise that a second splicing factor under the control of FMRP is involved in this splicing event. Another possibility is that any remaining *Mbnl1* RNA, which persists after *Mbnl1* knockdown, might undergo further dysregulation following *Fmr1* knockdown.

Figure 3. RNA binding proteins control specific splicing events in *Fmr1*-depleted N2A cells.

(A) Consensus binding motifs of hnRNPF, hnRNPQ, MBNL, and PTBP flanking skipped or included exons of *Mapt* (exon 4), *App* (exon 8), and *Tnik* (exon 21) RNAs. Created with SFmap and Biorender.com.

(B) FMRP-dependent MBNL1, PTBP1, hnRNPF, and hnRNPQ-regulated splicing of *Mapt* exon 4. All RT-PCR determinations were made relative to GAPDH or actin (relative expression) and were performed in triplicate. P-values were calculated using one-way ANOVA and mean ± S.D is shown. *$p < 0.05$; **$p < 0.01$; ***$p < 0.001$; ****$p < 0.0001$.

(C) FMRP-dependent MBNL1, PTBP1, hnRNPF, and hnRNPQ-regulated splicing of *App* exon 8. All RT-PCR determinations were made relative to GAPDH or actin (relative expression) and were performed in triplicate. P-values were calculated using one-way ANOVA and mean ± S.D is shown. *$p < 0.05$; **$p < 0.01$; ***$p < 0.001$; ****$p < 0.0001$.

(D) FMRP-dependent MBNL1, PTBP1, hnRNPF, and hnRNPQ-regulated splicing of *Tnik* exon 21. All RT-qPCR determinations were made relative to GAPDH or actin (relative expression) and

were performed in triplicate. P-values were calculated using one-way ANOVA and mean ± S.D is shown. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

(E) Summary of exon inclusion/skipping following *Fmr1* and/or splicing factor depletion from N2A cells.

We next examined *App* exon 8, which is also flanked by MBNL, PTBP, hnRNPF, and hnRNPQ binding sites, is skipped more frequently upon *Fmr1* depletion compared to control. *Mbnl1* depletion caused *App* exon 8 skipping at the same frequency as *Fmr1* depletion. A double depletion of *Mbnl1* and *Fmr1* was not additive for exon 8 skipping (**Fig 3C**). Depletion of *hnRNPF*, however, caused increased skipping of *App* exon 8 similar to that observed when *Fmr1* was depleted. A double depletion was not additive for exon skipping. *hnRNPQ* depletion did not result in any change in *App* exon 8 skipping. Depletion of these factors had little effect on skipping/inclusion of constitutive *App* exon 2 (**S3Q-T**).

Finally, we examined *Tnik* exon 21, which is flanked by the same splicing factor binding sites, was included more frequently when *Fmr1* is depleted (**Fig 3D**). While *Mbnl1* depletion had no effect on *Tnik* exon 21 skipping/inclusion, depletion of both *Ptbp1* and *hnRNPF* caused greater inclusion relative to controls (**Fig 3D**)**.** Depletion of these factors had little effect on *Tnik* constitutive exon 25 (**S3Q-T**). A summary of all these data demonstrates that FMRP regulation of certain splicing factors influences inclusion or skipping of specific exons (**Fig 3E**).

To assess whether sequences surrounding an exon regulated by FMRP are bound by these RBPs, we analyzed published CLIP-seq and RIP-seq datasets for MBNL1 and PTBP1 [28, 29]. We detected MBNL1 binding sites in *Mapt* exon 4, as supported by RIP-seq data. We also observed MBNL1 binding sites downstream of *App* exon 8, as evidenced by CLIP-seq data, and

similarly in *Ski* exon 2 based on a combination of RIP-seq and CLIP-seq findings (**S4**). We found PTBP1 binding sites, characterized by the TCTCTC/CTCTCT motif, upstream of *Mapt* exon 4, both upstream and downstream of *App* exon 8, and upstream of *Ski* exon 2. Moreover, PTBP1 binding sites were situated downstream of *Tnik* exon 21 (**S5**).

FMRP regulates *Mbnl1* RNA translation

To determine whether FMRP might regulate splicing factor expression directly, we first performed RNA co-immunoprecipitation experiments followed by RT-PCR for splicing factor RNAs. **Fig 4A** demonstrates that FMRP co-immunoprecipitated *Mbnl1* and *Ptbp1* RNAs relative to an IgG control. For comparison, Maurin et al demonstrated that mouse brain FMRP UV-CLIPs to *Mbnl1* RNA [10]. We further found that around 50% of skipped or included exons in N2A cells contain binding sites for MBNL1, while non-target exons contain binding sites at a rate of 36% (**Data S1** and **Data S2**) using RBPmap [30].

Figure 4. FMRP regulation of *Mbnl1* RNA translation and isoform switching.

(A) Co-immunoprecipitation of *Mbnl1*, *Ptbp1*, *hnRNPF*, *hnRNPQ*, and *Srsf5* RNAs with FMRP. IgG and *Srsf5* RNA served as a immunoprecipitation controls. All experiments were performed in triplicate. P-values were calculated using one-way ANOVA and mean ± S.D is shown. *$p < 0.05$; ****$p < 0.0001$.

(B) Western blotting and quantification of splicing factors from control and *Fmr1*-depleted cells. Histogram represents band intensity quantification and mean ± S.D is shown (Student's t-test, *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$).

(C) Western blotting and quantification of MBNL1 in control and *Fmr1*-depleted cells following addition of the proteasome inhibitors MG132 or lactacystine for 0-4 or 6 hours. The histograms represent MBNL1 band intensities relative to GAPDH or tubulin.

Western blotting of the splicing factors showed that MBNL1 and hnRNPQ were elevated ~1.5-2 fold upon *Fmr1*-depletion (**Fig 4B**). Because neither *Mbnl1* nor *hnRNPQ* RNAs are altered by *Fmr1* depletion (**S3B and H**), we infer that these two RNAs are under negative translational control by FMRP. Additional data showing that MBNL1 displays no differential stability in control versus *Fmr1*-depleted cells incubated with the proteasome inhibitors MG132 or lactacystine further indicate FMRP control of *Mbnl1* RNA translation (**Fig 4C**). MBNL1 and hnRNPQ are each represented by two isoforms; in the case of MBNL1, the slow migrating isoform is reduced when *Fmr1* is depleted while the fast migrating form is increased (**Fig 4B**)**.** For hnRNPQ, the slow migrating isoform is unaffected while the fast migrating isoform is increased upon *Fmr1* depletion (**Fig 4B**). Neither PTBP1 nor hnRNPF undergo abundance changes in *Fmr1*-depleted cells (**Fig 4B**).

FMRP regulates *Mbnl1* RNA auto-splicing and MBNL1 localization

Two of the most frequently alternatively spliced exons of *Mbnl1* mRNA are exon 5 and exon 7 (**Fig 5A**), of which exon 5 skipping arises by autoregulated splicing [31-33]. To determine whether alternative *Mbnl1* auto-splicing is under FMRP control and involves either of these two exons, we performed RT-PCR with primers that distinguish between these exons. **Fig 5B** shows that exon 5 is skipped more frequently upon *Fmr1* depletion while exon 7 and exon 10 (constitutive exon) skipping is unaffected.

Exon 5, which contains a nuclear localization signal (NLS), determines whether MBNL1 is predominantly nuclear or is distributed to both nucleus and cytoplasm [33, 34]. To assess whether exon 5 skipping upon *Fmr1* depletion alters the nucleus/cytoplasmic ratio of MBNL1, we first performed western blots of protein from cells fractionated into these two compartments. **Fig 5C** shows that MBNL1 containing the NLS encoded by exon 5 (i.e., the upper band) decreased in the cytoplasm following *Fmr1* depletion. Conversely, the NLS-lacking MBNL1 (lower band) increased in the cytoplasm when *Fmr1* was depleted. The upper NLS-containing band was decreased in the nucleus after *Fmr1* depletion. Immunocytochemical analysis of intact cells also shows that the MBNL1 nucleus/cytoplasmic ratio decreased upon *Fmr1* depletion (**Fig 5D**), which is in concordance with the cell fractionation results.

Figure 5. FMRP control of isoform switching regulates nucleus/cytoplasmic distribution of MBNL1.

(A) Schematic illustration of *Mbnl1* isoforms (modified from Tabaglio et al [35]). Exons 5 and 7 are the most frequently alternatively spliced exons. Created with Biorender.com.

(B) RT-PCR of *Mbnl1* isoforms from control and *Fmr1*-depleted cell. At right is quantification of band intensities of exons 5 and 7 and mean ± S.D is shown (Student's t-test, $^{**}p < 0.01$). The constitutive exon 10 was amplified to compare total *Mbnl1* RNA expression between the genotypes.

(C) MBNL1 isoforms in the cytoplasm and nucleus in control and *Fmr1* knockdown cells. Lamin B1 and tubulin served as makers for the nuclear and cytoplasmic fractions, respectively. Quantification of the upper and lower MBNL1 bands relative to tubulin or Lamin B1 is indicated. Mean ± S.D is shown (Student's t-test, $^{*}p < 0.05$, $^{**}p < 0.01$).

(D) Immunocytochemical localization of FMRP, and MBNL1 in N2A cells following *Fmr1* depletion. Quantification of the nucleus/cytoplasmic ratio of MBNL1 fluorescence intensity is at right. Mean ± S.E.M is shown (Student's t-test, $^{**}p < 0.01$). Magnification 63X. Scale bar, 20 microns.

(E) Immunocytochemistry of FMRP and SC35 in N2A cells. Magnification 63X.

FMRP shuttles to the nucleus [36] where it has been reported to co-localize with Cajal bodies [37], membrane-less structures that frequently coincide with the nucleolus. We detected a low amount of FMRP in the nucleus of N2A cells and considered that it may also associate with splicing factor-rich nuclear speckles [38]. Immunostaining for splicing factor SC35, which detects a few splicing proteins [39], showed abundant nuclear speckles but were not co-localized with FMRP, suggesting that FMRP is unlikely to regulate splicing directly (**Fig 5E**).

Because we had identified a correlation between elevated SETD2, dys-regulated H3K36me3 chromatin marks, and altered splicing in *Fmr1* KO mouse hippocampus [15], we considered this might also occur in FMRP-deficient N2A cells. However, we observed no change in SETD2 levels in these cells, indicating that a changed chromatin landscape and altered splicing in FMRP-deficient cells may not be linked (**S6A**).

Alternative splicing of *Mbnl1* RNA in FMRP-deficient cells and tissues

We analyzed published datasets to determine whether *Mbnl1* exon skipping occurs in the FMRP-deficient tissues. **Fig 6A** shows that Mbnl1 exon 5 skipping is detected not only in *Fmr1*-depleted N2A cells, but also in mouse *Fmr1* KO peripheral tissues (liver, muscle, testis). Moreover, exon 7, which is important for MBNL1 self-dimerization, is skipped in several peripheral tissues as well as cerebellum. Although the precise function of the dimerization is unclear, exon 7 residues are thought to increase MBNL1 affinity for RNA [40]. Somewhat surprisingly, we did not detect exon 5 skipping in mouse brain, although it and exon 4 were mutually exclusive exons in human Fragile X postmortem brain. For *Mbnl2* RNA, we found that exon 5 skipping is increased in *Fmr1*-depleted

N2A cells, but that exon 5 is more included in mouse *Fmr1* KO HC. These data show that FMRP-regulated alternative splicing of *Mbnl1* and *Mbnl2* is widespread, but that the exons involved in the splicing events vary according to tissue. It has been reported that specific exons are differentially alternatively spliced in various tissues due to different amounts/activities of splicing factors [41-43]. Our investigation confirms that FMRP not only influences the splicing of Mbnl1, but also impacts the splicing of several other RNA-binding protein mRNAs. Moreover, this effect of FMRP on splicing patterns is different across different tissue types.

Fig 6. Alternative splicing of *Mbnl1* RNA in FMRP-deficient cells and tissues.

The figure shows the tissue type and frequency where specific exons in *Mbnl1* RNA mis-spliced upon FMRP depletion [33, 44-47].

Effect of FMRP on splicing decisions by MBNL2 and PTBP2

MBNL1 and its paralog MBNL2 have the same binding sites on mRNA [28] as do the PTBP1 and its paralog PTBP2 [29]. *Mbnl2* and *Ptbp2* RNAs are present in N2A cells, but at lower levels that *Mbnl1* (by ~2 fold) and P*tbp2* (by ~8 fold) RNAs, respectively (**Fig 7A**). Depletion of *Fmr1* had no significant effect on *Mbnl2* RNA, but interestingly, it increased MBNL2 protein levels and induced MBNL2 auto-splicing of exon 5 (**Fig 7B, S4B**). Similar to *Mbnl1*, *Mbnl2* exon 5 bears an NLS, and thus determines the nuclear/cytoplasmic localization of this protein [40]. Moreover, *Mbnl2* RNA has been reported as a binding target of FMRP [10]. Depletion of *Fmr1* caused a reduction of *Ptbp2* RNA levels, but had no effect on PTBP2 protein levels (**Fig 7B**). Depletion of *Mbnl2* elicited an increase in *Mapt* exon 4 inclusion, significantly greater that *Mbnl1* depletion (**Fig 7C**). These data suggest that MBNL1 and MBNL2 may both contribute to FMRP-controlled alternative splicing, but that PTBP2 is likely to have no significant effect.

Figure 7. MBNL2 and PTPB2 are modestly down-regulated in Fmr1-deficient cells.

(A) *Mbnl1, Mbnl2*, *Ptbp1*, and *Ptbp2* RNA levels (in Ct value) N2A cells.

(B) RT-pPCR analyses and representative western blots showing *Mbnl2* and protein levels following *Fmr1* depletion. Quantification of the MBNL2/GAPDH band intensity from 5 independent experiments is at the right. Mean ± S.D is shown (Student's t-test, *p < 0.05).

(C) RT-pPCR analyses and western blots showing *Ptbp2* RNA and protein levels following *Fmr1* depletion. Quantification of the MBNL2/GAPDH band intensity is at the right. Mean ± S.D is shown (Student's t-test, ****p < 0.0001).

(D) *Mbnl1* and *Mbnl2* expression as well as *Mapt* exon 4 inclusion/skipping following *Mbnl1* or *Mbnl2* depletion. P-values were calculated using one-way ANOVA and mean ± S.D is shown (***p < 0.001; ****p < 0.0001).

(E) *Ptbp1* and *Ptbp2* expression as well as *Mapt* exon 4 inclusion/skipping following *Ptbp1* or *Ptbp2* depletion. P-values were calculated using one-way ANOVA and mean ± S.D is shown (*p < 0.05, **p <0.01, ***p < 0.001; ****p < 0.0001).

We propose that in N2A cells, *Mbnl1* pre-mRNA undergoes alternative splicing such that exon 5-containing and exon 5-lacking mRNAs are exported to the cytoplasm where they are bound by FMRP, which limits their translation. The MBNL1 protein that retains the NLS-encoding exon 5 is transported to the nucleus where it could influence alternative splicing of other pre-mRNAs. In *Fmr1*-deficient cells, exon 5-lacking *Mbnl1* RNA is elevated in the cytoplasm relative to exon 5-containing RNA, but because there is no FMRP to limit translation in these cells, MBNL1 synthesis is robust, which is particularly the case for those *Mbnl*1 mRNAs that lack exon 5 NLS. As a consequence, there is reduced MBNL1 transported to the nucleus, which may in turn have

adverse effects on RNA splicing relative to normal cells. As presented in this study, MBNL1 is only one of several proteins through which FMRP regulates splicing.

Global transcriptomic changes induced by FMRP and MBNL1

To investigate whether FMRP-mediated splicing is influenced by the absence of nuclear MBNL1, we devised an experiment involving expression of either nuclear or cytoplasmic MBNL1 isoforms. As a rescue strategy, the depletion of *Fmr1* combined with the overexpression of the nuclear MBNL1 isoform (siFmr1+nMBNL1). To identify the distinct changes that could occur from the loss of the nMBNL1, the depletion of Mbnl1 coupled with the overexpression of the cytoplasmic MBNL1 isoform lacking exon 5 (siMbnl1+cMBNL1) (**Fig 8A**). Using the nMBNL1 and cMBNL1 plasmids, the localization of the expressed RNA in the nucleus and cytoplasm, respectively has been previously elucidated [48]. We validated the knockdown and overexpression of *Fmr1* and *Mbnl1* through qPCR analysis (**Fig 8B** and **S7A**). It is important to note that the depletion of *Fmr1* or *Mbnl1* did not exert a significant impact on each other. As shown in Fig 8C, the overexpression of nuclear MBNL1 led to an increase in *Mbnl1* exon 5 inclusion, whereas overexpression of cytoplasmic MBNL1 resulted in a decrease in exon 5 inclusion.

To gain deeper insights into the global transcriptomic changes mediated by *Fmr1* and *Mbnl1*, we performed RNA-seq experiments. Consistent with the qPCR data in **Fig 8B**, we observed a substantial reduction in the normalized counts of *Fmr1* or *Mbnl1* in the knockdown groups and an elevation in the levels of MBNL1 isoforms in the overexpressed groups, as depicted in **Fig 8D**. The volcano plots provide evidence of numerous significant alterations in mRNA expression under *Fmr1* or *Mbnl1* single knockdown conditions (**Fig 8E** and **Fig 8F**, with $\log_2 FC > 0.2$ or < -0.2, and FDR < 0.05; n=3).

Strikingly, there were 660 common differentially expressed genes observed between *Fmr1* knockdown and *Mbnl1* knockdown conditions as indicated in the Venn diagram presented in **Fig 8G**. Of these, 377 genes exhibited upregulation, while 236 genes were downregulated in both experimental groups. **Fig 8H** highlights specific examples of these shared differentially expressed genes. For instance, *Kcnab1*, encoding voltage-gated potassium channels that regulate neurotransmitter release, showed an increase in expression upon depletion of either *Fmr1* or *Mbnl1*. On the other hand, *Dr1*, encoding TBP-associated phosphoprotein that represses both basal and activated transcription levels, displayed reduced expression upon *Mbnl1* depletion. Additionally, *Ccl2*, responsible for encoding monocyte chemoattractant protein-1 (MCP-1), exhibited increased expression upon *Fmr1* depletion.

Figure 8. Differential gene expression in *Fmr1* or *Mbnl1* depleted cells.

(A) Schematic of experiment. Created with BioRender.com

(B) qPCR showing depletion of *Fmr1* following *Fmr1* or *Mbnl1* knockdown using siRNA. At right, qPCR results demonstrate the overexpression of *Mbnl1*. P-values were calculated using one-way ANOVA and mean ± S.D is shown (**$p < 0.01$; ****$p < 0.0001$).

(C) qPCR of *Mbnl1* exon 5 skipping/inclusion. P-values were calculated using one-way ANOVA and mean ± S.D is shown (****$p < 0.0001$).

(D) Normalized gene counts of *Fmr1* and *Mbnl1* in the experimental conditions.

(E) Volcano plots of differential gene expression comparing siNT and siFmr1. The top six significantly altered genes are labeled. At right, volcano plots of differential gene expression comparing siNT and siMbnl1. The top six significantly altered genes, along with *Mbnl1*, are labeled.

(F) Venn diagram presenting the comparison of RNAs regulated by *Fmr1* and *Mbnl1*.

(G) Normalized gene counts of representative RNAs that are regulated by *Fmr1* and/or *Mbnl1*.

FMRP-mediated SE events are regulated by nuclear MBNL1

To elucidate the role of MBNL1 in mediating splicing events associated with FMRP, we conducted a comprehensive investigation of alternative splicing events across various groups. Our analysis revealed a substantial number of splicing alterations in cells depleted of *Fmr1* either *Mbnl1*, with notable emphasis on changes within the SE and MXE categories (**Fig 9A**, **Fig 9B**, and **S8A**).

We successfully validated that the skipping of *Mbnl1* exon 5 occurs upon *Fmr1* depletion, and is included upon nMBNL1 overexpression. Conversely, *Mbnl1* depletion and cotransfection with cMBNL1 results in cytoplasmic MBNL1 (**S8B**). Comparing SE under both conditions, we identified an overlap of 1458 RNAs between *Fmr1* and *Mbnl1* depleted cells, constituting over half of each dataset (**Fig 9C**). Among these, 1393 RNAs had the same alternative exon between the two groups (**S8C**). Our correlation analysis based on delta PSI values indicated a robust and statistically significant positive correlation between *Fmr1* and *Mbnl1* depleted cells, with a correlation coefficient (r) of 0.8382, R-squared (R^2) value of 0.7026, and p-value of less than 0.0001 (**Fig 9D**).

We next examined whether splicing could be rescued by overexpression of nuclear MBNL1, which includes exon 5, in *Fmr1*-depleted cells. Remarkably, we found that 21% of mis-spliced exons in *Fmr1*-depleted cells were restored by nuclear MBNL1 (**Fig 9E**). Specific examples include *Thap7* exon 2 and *Slc30a4* exon 2, where *Fmr1* knockdown disrupted splicing, but nMBNL1 overexpression reversed this effect (**Fig 9G**). We extended our inquiry to include a comparison of splicing events in *Fmr1* depleted cells and cytoplasmic MBNL1 overexpressed cells, which had a reduced level of endogenous *Mbnl1*. Notably, 37% of mis-spliced exons in *Fmr1*-depleted cells exhibited congruent splicing patterns with the siFmr1 in the siMbnl1+cMBNL1 group, including *Rps24* exon 5 and *Atp2a3* exon 21 (**Fig 9F** and **Fig 9H**).

Furthermore, we uncovered splicing factors whose mRNA expression or splicing patterns were altered exclusively in *Fmr1*-depleted cells and not in *Mbnl1*-depleted cells. This observation suggests the existence of non-MBNL1-mediated mechanisms contributing to splicing regulation under *Fmr1-depletion* (**S9A** and **S9B**).

Figure 9. FMRP regulates alternative splicing through redistribution of MBNL1 isoforms.

(A) Changes in alternative RNA splicing across categories.

(B) Violin plots illustrating the distribution of delta PSI in siFmr1 and siMbnl1 cells. The solid line is the median and the dashed lines are quartiles. P-value < 0.05, |delta PSI| > 0.05.

(C) Venn diagram comparing RNAs exhibiting skipped exon events in siFmr1 and siMbnl1 cells.

(D) Correlation plot showing the relationship of delta PSI values between siFmr1 and siMbnl1 conditions.

(E) Heatmap visualizing the PSI values of mis-spliced RNAs in siFmr1 cells, rescued by the overexpression of nMBNL1. PSI values were adjusted by z-score.

(F) Heatmap displaying the PSI values of mis-spliced RNAs in siFmr1 cells and siMbnl1+cMBNL1, which is similar to the splicing changes upon *Fmr1*-depletion. PSI values were adjusted by z-score.

(G) PSI values of representative spliced exons, rescued by nMBNL1 (*Thap7* exon 2 and *Slc30a4* exon 2).

(H) PSI values presented for a representative spliced exon, showing alterations in the same direction in both siFmr1 and siMbnl1+cMBNL1 conditions (*Rps24* exon 5 and *Atp2a3* exon 21).

Discussion

The proteome of the hippocampus, an exceptionally well-studied brain region of Fragile X Syndrome model mice, is largely attributed to altered mRNA translation with perhaps a minor contribution of protein degradation [3, 49-51]. This study indicates that mis-regulated alternative splicing may be a contributor to the Fragile X proteome not only in the hippocampus and other brain regions of *Fmr1*-deficient mice, but in peripheral tissues as well. Our investigation of the mechanism of FMRP-mediated splicing used *Fmr1*-deficient N2A cells, which was based on the assumption that a single cell type would more likely reveal the involvement of specific factors than a complex mixture of cells such as in the brain. By mapping splicing factor binding sites flanking certain skipped or included exons in 3 mRNAs in *Fmr1*-depleted cells, we found that four proteins: MBNL1/2, PTBP1, and hnRNPF contribute to alternative splicing mis-regulation, and MBNL1/2 and hnRNPQ, are translationally inhibited by FMRP. Moreover, *Mbnl1/2* auto-splicing induced skipping of the NLS-containing exon 5, which is thought to be enhanced by elevated levels of MBNL1/2 protein [40, 47], was observed. This event impairs MBNL1/2 nuclear transport, which in turn likely affects downstream splicing decisions. AS events altered by FMRP and MBNL1 demonstrate a robust positive correlation. Moreover, the ectopic expression of MBNL1 isoform containing the NLS within exon 5 reversed approximately one-fifth of the disrupted splicing pattern in *Fmr1*-depleted cells. Conversely, expression of mainly the cytoplasmic MBNL1 recapitulated a proportion of the splicing changes observed upon *Fmr1* depletion. In summary, our collective findings underscore the existence of discrete subsets of nuclear MBNL1-mediated splicing events within the context of *Fmr1*-regulated splicing.

Mbnl1 exon 5 is also skipped in *Fmr1*-deficient mouse peripheral tissues as well as in human postmortem Fragile X brain. Exons 6, 7, and 8 are skipped in neural stem cells, and/or liver,

muscle, testis, and cerebellum from *Fmr1*-deficient mice. Thus, FMRP regulation of *Mbnl1* splicing is complex and is strongly influenced by cell/tissue-type, which likely contributes to downstream splicing regulation.

The regulation of splicing via MBNL1/2 is only one of several FMRP-dependent mechanisms that mediate RNA processing. PTBP1 and hnRNPF all influence splicing decisions that are downstream of FMRP. For both MBNL1 and hnRNPQ, this involves FMRP-regulated translation of their respective mRNAs. In this sense, FMRP control of splicing is similar to FMRP control of chromatin modifications and transcription; the root cause of the alteration of these molecular events is dys-regulated translation when FMRP is absent [15, 19]. We also considered whether FMRP might influence splicing directly. It is a nuclear shuttling protein that at least in mouse testis, binds chromatin and is involved in the DNA damage response [52]. FMRP co-localizes with Cajal bodies in Hela cells, which implies it may modify rRNA biogenesis [37]. We inferred that if FMRP was a direct regulator of splicing, it would co-localize with SC35-containing nuclear splicing/processing bodies or speckles [38]. We did not detect any such co-localization and thus FMRP is unlikely to be a direct modulator of splicing. In addition, we previously reported a correlation between the up-regulation of SETD2, altered H3K36me3 chromatin marks, and RNA splicing mis-regulation in *Fmr1*-deficient mouse brain [15]. In *Fmr1* KO N2A cells, however, we detected no alteration in SETD2 levels, and thus a change in H3K36me3 leading to splicing dys-regulation is unlikely. The notable disparity observed between the brain and the cellular model serves to highlight the intricacies of molecular regulation and the intricate manner in which FMRP-mediated processes operate. The multifaceted interplay involving FMRP, SETD2, splicing factors, and the dysregulation of splicing emphasizes the need for a more comprehensive investigation into the mechanisms upon the specific cellular context.

In most cases, the dys-regulated inclusion/exclusion of exons in *Fmr1*-deficient tissues/cells has a mean of ~20%, but with a large distribution. Although the magnitude of such changes is within the range often observed for alternative splicing [53], it is unclear to what extent these splicing changes have biological consequences. However, even modest changes in exon skipping can manifest themselves with changes in biology if a skipped exon is regulatory. For example, an exon encoding a regulatory phosphorylation site in the RNA binding protein CPEB4 is skipped <30% of the time but this skipping is correlated with if not causative for autism [54]. In the *Fmr1* KO mouse, we cannot ascribe any single mis-splicing event as contributing to a Fragile X phenotype. Instead, it is more likely that the amalgamation of hundreds of mis-splicing events result in some Fragile X pathophysiology, for example, dys-regulated synaptic transmission or learning and memory [7, 55].

Finally, the dys-regulated splicing in Fragile X model mice may represent a point of convergence with other neurodevelopmental disorders [56]. For example, splicing is impaired in autism spectrum disorders [57], Rett Syndrome [58], Pten [59], and others [15]. Whether mis-splicing in these disorders are related mechanistically is unclear, but they may involve several of the same factors (e.g., MBNL1, PTBP1). More intriguing is the prospect that some mis-splicing events link similar behavioral or other physiological impairments among these disorders. This may especially be the case when very small microexons encoding regulatory domains are skipped [60]. Future studies will be necessary determine whether specific mis-splicing events promote pathophysiolgical outcomes.

Materials and Methods

Animals

Mice were housed under a 12 h light/dark cycle with free access to food and water. Wild-type and *Fmr1* KO mice were purchased from the Jackson Laboratories. Two to three month old male mice were used in this study (n=3 each for WT and *Fmr1* KO). Animal maintenance and experimental procedures were performed accordance with all animal research guidelines from University of Massachusetts Chan Medical School.

Cell culture and siRNA transfection

Mouse N2A cells were cultured in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics. The siRNAs targeting *Fmr1*, *Ptbp1, Ptbp2, hnRNPF*, *hnRNPQ, Mbnl1*, and *Mbnl2* were purchased from IDT. As a negative control siRNA, siNT (ON-TARGETplus) was purchased from Dharmacon. For siRNA transfection, $1x10^5$ cells were seeded in 6-well plates overnight and transfected with 20-25 pmol of the indicated siRNAs using Lipofectamine 3000 (ThermoFisher Scientific, 13778030) following the manufacturer's instructions. For double depletion experiments, cells were transfected in triplicate as follows: 1) siNT (80 pmol), 2) siFmr1 (40 pmol) + siNT (40 pmol), 3) siMbnl1 (40 pmol) + siNT (40 pmol), 4) siFmr1 (40 pmol) + siMbnl1 (40 pmol). Cells were incubated with the indicated siRNAs for 48-72 h before being analyzed. For co-transfection of siRNA and DNA, N2A cells were transfected with 25 pmol of siRNA and 1 µg of DNA with 7.5ul of lipofectamine 3000. Cells were collected 72 h after transfection.

RT-PCR and qPCR

Total RNA was isolated using TRIzol-LS (Invitrogen, 10296-028) and total RNA (1 µg) was reverse transcribed using QuantiTect Reverse Transcription Kit (Qiagen, 205313) according to manufacturer's instructions. RT-PCR was performed using GoTaq Green Master Mix (Promega, M7123). 2 µl of diluted cDNA was added to 12.5 µl GoTaq Green Master Mix and 0.4 µM of forward and reverse primers and nuclease-free water in a 25 µl reaction. PCR amplification was performed as follow: initial denaturation at 95 °C for 2 min, 30 cycles of denaturation at 95 °C for 30 s, annealing at each primer's annealing temperature for 1 min, and 72 °C for 1 min/kb and final extension at 72 °C for 5min. qPCR was performed with QuantStudio3 (ThermoFisher Scientific) as follow: initial denaturation at 95 °C for 10 min, 39 cycles of denaturation at 95 °C for 15 s annealing and extension at 60 °C for 1 min. Exon inclusion and exclusion levels were quantified using qPCR. For alternative splicing validation, primers were designed to specifically amplify exon-exon junctions of the included or skipped isoform. A primer pair amplifying a constitutive exon in each mRNA was used to determine changes in total mRNA expression between genotypes. Primer sequence information is listed below.

Western blot

Cells were washed with ice-cold PBS and collected using trypsin to release them from the plasticware. After centrifugation, the cells were lysed with ice-cold RIPA buffer (NaCl 150 mM, Triton X-100 1%, sodium deoxycholate 0.5%, SDS 0.1% and Tris-HCl 50 mM pH 8.0) with cOmplete Mini EDTA-free protease inhibitor cocktail (MilliporeSigma, 11836170001) and PhosSTOP (MilliporeSigma, 4906837001) and rotated for 10 min at 4 °C. The lysates were collected by centrifugation at 12,000 rpm for 10 min at 4 °C. Supernatants were removed and the protein concentration was quantified using the colorimetric assay by Pierce™ BCA protein assay kit (ThermoFisher Scientific, 23225). Protein lysates were resolved using 10% SDS-PAGE gels

and transferred to 0.45 µm PVDF membranes (Millipore, IPVH00010). The membranes were blocked in 5% skim milk solution for 1 h at RT then incubated with primary antibody at 4 ℃ overnight: Anti-FMRP antibody (Abcam, ab17722, 1:1,000), anti-GAPDH antibody (Cell signaling technology, 2118, 1:1,000), anti-alpha-Tubulin (MilliporeSigma, T5168, 1:1,000), anti-Lamin B1(Abcam, ab16048, 1:2,000), anti-MBNL1 (Cell signaling technology, 94633, 1:1,000), anti-MBNL2 (Cell signaling technology, 93182, 1:1000), anti-PTBP1 (Cell signaling technology, 57246, 1:1,000), anti-PTBP2 (Cell signaling technology, 59753, 1:1,000), anti-hnRNPF (Novusbio, NBP2-57442-25 µl, 1:1,000), anti-hnRNPQ (Abclonal, A9609, 1:1,000), anti-SETD2 (Abclonal, A11271, 1:1,000), anti-histone H3K36me3 (Abcam, ab9050, 1:1000), anti-histone H3 (Abcam, ab18521, 1:1000). The membranes were incubated with horse radish peroxidase (HRP)-linked secondary anti-rabbit (Jackson ImmunoResearch, 211-032-171, 1:5,000) or anti-mouse (Jackson ImmunoResearch, 115-035-174, 1:5,000) antibody and developed with ECL (Pierce, NEL105001EA). Immunoreactive bands were detected using GE Amersham Imager.

Cytosol and nuclear protein fractionation

Cells were washed with ice-cold PBS, collected by trypsinization, pellets collected by centrifugation, and then resuspended in Triton extraction buffer (TEB, PBS containing 0.5% triton X-100 (v/v), 2 mM phenylmethylsulfonyl fluoride, 0.02% NaN_3) and lysed on ice for 10 min. Following a centrifugation at 12,000 rpm at 4 °C, the supernatants were saved for cytoplasmic protein and the pellets were resuspended in nuclear lysis buffer (50 mM Tris-HCl pH 7.4, 120 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS) and lysed by sonication at high power for 8 cycles (15 sec on, 60 sec off) using a Bioruptor (Diagenode). The lysates were collected after centrifugation at 13,000 rpm for 10 min at 4 °C and the supernatants were prepared for nuclear protein analysis. Nuclear and cytoplasmic protein concentrations were measured using BCA assays.

RNA-seq

Mouse tissues were powdered in liquid nitrogen with a frozen mortar and pestle. For RNA extraction, TRIzol was added to the tissue powder and homogenized with Dounce tissue homogenizer. The RNA was treated with TurboDNase (Invitrogen, AM2238) to remove genomic DNA contamination. For peripheral tissues and N2A cells, total RNA was extracted and the integrity analyzed by a fragment analyzer. Library preparation and RNA sequencing were performed by Novogene (CA, USA). For brain samples, polyadenylated mRNA was enriched using Nextflex Poly(A) Beads (NEXTflex, Bioo Scientific Corp, 512980) and cDNA libraries were prepared using a NEXTflex Rapid Directional qRNA-Seq Kit (Bioo Scientific Corp, NOVA-5130-03D). In brief, the mRNA was randomly fragmented, reverse transcribed, and double-stranded cDNA was adenylated and ligated to index adapters. The cDNA was amplified by PCR and purified with AMPure beads (Beckman Coulter, A63881). The libraries were quantified with a KAPA Library Quantification Kit (KAPA Biosystems, KK4873) and the quality and size were analyzed by a fragment analyzer. Pooled libraries were sequenced on an NextSeq500 Sequencer using NextSeq 500/550 High Output Kit v2.5 (Illumina, 20024906, 75 base paired ends).

Differential expression and alternative splicing analysis

RNA-seq analysis was performed using DolphinNext pipeline at UMass Chan Medical School [61]. Quality trimming was conducted using Fastqc (v0.11.8) and Trimmomatic (v.0.39). Reads below a minimum quality PHRED score of 15 at the 10nt sliding window were first clipped and the clipped reads shorter than 25nt were trimmed. The trimmed reads were mapped to rRNA by Bowtie2 (v2.3.5) were further filtered out. The cleaned reads were aligned to the mouse reference genome (mm10) with STAR (v1.16.1), and gene expression was quantified by RSEM (v1.3.1). Differential gene expression was analyzed using DESeq2 (v1.16.1). The FDR adjusted p-value < 0.05 and $\log_2 FC > 0.2$ or < -0.2 was used as the cut-offs to identify the differentially expressed

genes. Alternative splicing events are analyzed using rMATS (v3.0.9) [62] and p-value < 0.05 and |delta PSI|> 0.05 was used as the cut-offs for splicing events. To assess biological function, Gene Ontology (GO) term analysis was conducted using clusterProfiler R package [63, 64]. Significant RNA Overlap from WT and *Fmr1* KO hippocampus, cortex, and cerebellum was analyzed using DynaVenn [65] using p-value ordered RNA list.

Generation of an *Fmr1* CRISPR/Cas9-edited cell line

To construct an *Fmr1* KO N2A mouse cell line, an *Fmr1* exon 3 DNA oligonucleotide was inserted into pLentiCRISPR (Addgene, 49535) adapted from published methods [12]. Briefly, annealed and phosphorylated oligonucleotides were cloned into a FastDigest BmsBI (Fermentas)-digested vector following the manufacturer's protocol. pLentiCRISPR-m*Fmr1*Exon3 was co-transfected with pMD2.G and psPAX2 into HEK293T cells. The viral particles containing supernatants were collected after 48 h of transfection by filtering through 0.45 µm filters and transduced to N2A cells. After 3 days of infection, transduced cells were selected with puromycin for 2 weeks. Puromycin resistant cells were seeded in each well of a 96 well plate with a single cell per well. Single cell-derived colonies were obtained after several weeks of culture and verified for *Fmr1* knockout by Sanger DNA sequencing and western blotting. For the sequencing, genomic DNA was extracted using lysis buffer (10 mM Tris 8.0, 200 mM NaCl, 20 mM EDTA. 0.2% Triton X-100 and 100 µg/ml proteinase K) and the deleted exon region was PCR amplified using primers (sequences noted below). To identify deleted sequences, the PCR products were cloned with a TOPO TA Cloning Kit (ThermoFisher Scientific, 450030) followed by sequencing using T7 primers (Genewiz).

Alternative splicing reporter system

To generate an alternative splicing reporter, total DNA was isolated from N2A cells using the lysis buffer described above. *Mapt* exon 4 and flanking the intron regions were PCR amplified using Phusion High-Fidelity DNA polymerase and inserted into NheI/BamHI digested pFlareA Plasmid

(Addgene, 90249) and sequenced. For MBNL1 binding site deletion mutant, the MBNL1 binding site (TGCTGC) was deleted using Q5 Site Directed Mutagenesis kit (NEB E0554). 12.5 ng of pFlareA-Mapt Ex4 splicing reporter was used as template and mixed with 12.5 µl of Q5 Hot Start High-Fidelity 2X Master Mix, 2.5 µl of 10 µM of each primer (Forward: CTCGGACCAGCCGAAGAA, Reverse: AAGGGAGAGGACAGAAGG), and 9 µl of nuclease free water. PCR amplification was performed with initial denaturation at 98 °C for 30 s, 25 cycles of denaturation at 98 °C for 10 s, annealing at 63 °C for 30 s, extension at 72 °C for 3 min 30 sec and final extension at 72 °C for 5 min. PCR product was treated with kinase, ligase and DpnI according to manufacturer's instruction. Deletion of MBNL1 binding site was confirmed by sanger sequencing.

Cultured N2A control and *Fmr1* CRISPR/Cas9 KO cells were seeded in 6-well plates overnight and then transfected using 7.5 µl of Lipofectamine 3000 (Invitrogen) and 5 µl of P3000 with the 1 µg of pFlareA-Mapt exon4 splicing reporter. For the rescue experiment, 1.5 µg of pcDNA-myc or pcDNA-mouse FMRP ectopic expression plasmids was added. Transfected cells were washed with PBS and collected by trypsinization 48 h after transfection. GFP and mCherry fluorescence intensities were detected using flow cytometry (LSR II A-5 Donald).

RNA-Immunoprecipitation (RNA-IP)

N2A cells were transfected with siNT and siFmr1 using Lipofectamine 3000. After 72 h of incubation, the cells were washed with fresh media containing 100 µg/ml cycloheximide (CHX, MilliporeSigma, C4859). After washing with ice-cold PBS-containing CHX, the cells were pelleted and lysed in 1X polysome buffer [20 mM Tris-HCl pH 7.5, 5 mM $MgCl_2$, 100 mM KCl, 1 mM DTT, 100 µg/ml CHX, protease inhibitor cocktails, 1 % Triton X-100 (v/v)] with 10 passages through a 25 G needle to triturate and incubated on ice for 10 min. The lysates were centrifuged at 14,000 x *g* at 4 °C and RNA concentration was measured using Qubit BR RNA Assay Kits (ThermoFisher

Scientific, Q10210). For IP, 5 µg of RNA was precleared with 25 µl of Protein G Dynabeads (Invitrogen, 10003D) for 30 min at 4 °C. 10% of aliquot of the precleared lysates were saved as an input. 2.5 µg of FMRP antibody (Abcam, ab17722) or IgG (MilliporeSigma, 12-370) was added to the precleared lysates and incubated for 2 h at 4 °C. 25 µl of Protein G Dynabeads was added and incubated for 30 min at 4 °C and the beads were gently washed with wash buffer [20 mM Tris-HCl, 100 mM KCl, 5 mM $MgCl_2$, 1% Triton X-100 (v/v)] for 3 times. RNA was extracted using TRIzol and 100 ng of RNA were reverse transcribed using Quantitect followed by qPCR using iTaq SYBRgreen (Bio-rad, 1725122).

Protein stability assay

N2A cells were transfected with siNT and siFmr1 using Lipofectamine3000. After 72h of incubation, cells were treated with 10 µM MG132 (MilliporeSigma, 474790) or Lactacystine (Tocris, 2267) and harvested at different time points.

Immunocytochemistry

For immunofluorescent staining, $1x10^5$ cells were seeded in a Chamber Slide (Nunc Lab-Tek II CC2, 154917) and transfected with 10 pmol siNT and siFmr1. After 48 h, cells were washed and fixed with 4 % formaldehyde solution (ThermoFisher Scientific, AAJ19943K2) for 10 min at RT. The fixed cells were washed with PBS three times and permeabilized using 0.1% Triton X-100 in PBS for 15 min at RT. The cells were washed with PBS three times and incubated with blocking buffer (1% BSA in PBS) for 1h at RT. Cells were then incubated overnight at 4 °C with primary antibodies anti-FMRP (Abcam, Ab17722, 1:500), anti-MBNL1 (ThermoFisher, 66837-IG, 1:100) or anti-Sc35 (MilliporeSigma, S4045, 1:1000) and incubated with the secondary antibodies using Alexa 488-labeled goat anti-mouse IgG (Abcam, Ab150113, 1:1000), Alexa 594-labeled goat anti-

rabbit IgG (ThermoFisher, A-10012, 1:250). Hoechst 33342 was used to stain the cell nuclei at 0.2 µg/ml for 15 min. Coverslips were mounted using FlourSave reagent (Milipore, 345789). Images were acquired using a Zeiss confocal microscope LSM900.

RBP binding exons

To determine whether sequences surrounding alternative exons are bound by MBNL1, CLIP-seq and RIP-seq data in MBNL Interactome Browser (MIB.amu.edu.pl) [28] were used. MBNL1 binding regions within alternative exons and/or adjacent intron of *Mapt*, *App*, *Ski* and *Tnik* were investigated. Using the CLIP list [29], alternative exons activated or inhibited by PTBP1 and regulated by FMRP were compared.

Data availability

RNA-seq datasets are available in GEO (accession number GSE207145).

Primers for validation of alternative splicing	
Dcun1d2 Ex6 RT F	ATGGCTGTTGCATATTGGAAGTT
Dcun1d2 Ex6 RT R	CAGGCGGCTTCTAAAGCACT
Dcun1d2 Ex2 RT F	GCTCAGAAGGACAAGGTCCG
Dcun1d2 Ex2 RT R	TAGACTCTCGGTGAAACGCC
Tnik SJC F	CGGCCAGCTGATCTGACG
Tnik SJC R	CTCACTGCTCTCCGACTCCT
Tnik IJC F	AAGTCCGAAGGATCACCCGT
Tnik IJC R	TGCCGTCAGATCCTCATCTAT
Tnik Ex20 F	ATCCAGAGACATCACACGGC
Tnik Ex22 R	TTCAGGGGGCGGTTTGTTT
Tnik Ex25 F	GGCCAAACTCAATGAAGCGA
Tnik Ex25 R	GGTGTGTCACTATGAGGGCG
Ski IJC F	GTGCCCCGGGTCTCA
Ski IJC R	GACGTCTCTTTCTCACTCGC

Ski SJC F	CCTGCCACTGGGGCTTC
Ski SJC R	AGCCGAGGCTCCGGG
Wnk1 SJC F	CAGGGAATACAGCCAACTGTTC
Wnk1 SJC R	ACTCCCTGAGTACTCTGTGTTC
Wnk1 IJC F	ACCTTGGCTTCATCTGCTACA
Wnk1 IJC R	TGAGTACTCTGGTACAAAACATCT
App SJC F	TGCTCTGAACAAGCCGAGAC
App SJC R	CTGTCGTGGGAAACACGCTG
App IJC F	GCAGCGTGTCAACCCAAAG
App IJC R	GGGACATTCTCTCTCGGTGC
Mapt SJC F	TGAACCAGTATGGCTGACCC
Mapt SJC R	GCTGGCCACACGAGCTTTTA
Mapt IJC F	TGGCTTAAAAGCCGAAGAAGC
Mapt IJC R	TCTTCTCGTCATTTCCTGTCCTG
Os9 SJC F	TGGACAAACTCATCAAGAGGCT
Os9 SJC R	AATCTTGCCTGTAGGGTGTGG
Os9 IJC F	ACCCTACAGAGGAGGAACCTG
Os9 IJC R	CAATCTTGCCTTCCGCCGTG
Mapt Ex15 F	AAAATCCGGAGAACGAAGCG
Mapt Ex15 R	AGGCGGCTCTTACTAGCTGA
App Ex2 F	TCGCCATGTTCTGTGGTAAAC
App Ex2 R	AATGCAGGTTTTGGTCCCTGA
Mbnl1 Ex5 RT F	TGCTCTCGGGAAAAGTGCAA
Mbnl1 Ex5 RT R	GGTGGGAGAAATGCTGTATGC
Mbnl1 Ex7 RT F	CCAACATGCAGTTACAGCAGC
Mbnl1 Ex7 RT R	GTTTTGTGACGACAGCTCTACA
Mbnl1 Ex10 F	ATGGTGAGGGAGGGAACTGA
Mbnl1 Ex10 R	GGTACTTAAAGCCATGGTGTGC
Mbnl2 Ex5 RT F	AAACGACAACACCGTAACCG
Mbnl2 Ex5 RT F	CTGGCCCCGTTGCTTTTT
Mbnl2 Ex9 RT F	CTCAGTTCAACAGCTCCGGT
Mbnl2 Ex9 RT R	TGTGACCAGTGGTGTATGGC

Primers for pFlareA reporter cloning

NheI-Mapt Ex4-BamHI-F	GCTAGCTAGCTTCTGGGTACA

NheI-Mapt Ex4-BamHI-R	CGCGGATCCAAGCGTATCTGTGAC

Primers for qPCR

Fmr1 F	ACCAAGAAAGAGTCACATTTAACCA
Fmr1 R	GGGGTAAAGAAACTTGGGACA
Gapdh F	CTACCCCCAATGTGTCCGTC
Gapdh R	TGAAGTCGCAGGAGACAACC
Mbnl1 F	AGCTGTACTTCCCCCATTGC
Mbnl1 R	AGCGGGTGTCATGCACAATA
Mbnl2 F	CAACTGTAGACCTGGCCTTCC
Mbnl2 R	TCATGGGTACTGTGGGGATGAA
Ptbp1 F	AGTGCGCATTACACTGTCCA
Ptbp1 R	CTTGAGGTCGTCCTCTGACA
Ptbp2 F	TACTAGCTGTTCCAGGGGCT
Ptbp2 R	AGGACTGTATTGCCACCAGC
hnRNPF F	CCACTCAACCCTGTGAGAGT
hnRNPF R	TTGCTAGCCCCTGTTGTTGA
hnRNPQ F	AGCCCATGGATACTACTTCAGC
hnRNPQ R	ATGTGCAACTAGCCCTGCAA
Srsf5 F	GGTGACGATTGAACATGCCC
Srsf5 R	CGACTGCTAAAACGGTCGGA

Primers for construction of CRISPR/Cas9 KO cell line

mFmr1-sgE3-F	CACCGTATTATAACCTACAGGTGGT	sgRNA for pLenticrispr
mFmr1-sgE3-R	AAACACCACCTGTAGGTTATAATAC	sgRNA for pLenticrispr
mFmr1 E3 GT F	ACCAAGAAAGAGTCACATTTAACCA	Deletion genotype primer
mFmr1 E3 GT R	GGGGTAAAGAAACTTGGGACA	Deletion genotype primer

Acknowledgments

We thank Dr. Guey Shin Wang (National Yang-Ming University and Academia Sinica, Taipei, Taiwan) for sharing FLAG-MBNL1^{Ex5}, FLAG-MBNL1$^{\Delta Ex5}$, and control plasmid. We thank Tammy Krumpoch and Susanne Pechhold (UMass Chan Medical School Flow cytometry core) for helpful discussions. We thank Dr. Ozkan Aydemir and Ms. SitharaRaju Ponny for advice on bioinformatic and statistical analysis and Dr. Heleen van't Spijker for assistance with immunofluorescence microscopy. We thank Dr. Mariya Ivshina for insightful conversations related to this study and Drs. Pablo Visconti and Maria Gracia Gervasi (University of Massachusetts Amherst) for assistance with some initial experiments. This work was supported by NIH grants GM046779, GM135087, NS132935, GM149216, UL1-TR001453, and a grant from FRAXA. SS was a FRAXA postdoctoral fellow.

References

1. Santoro MR, Bray SM, Warren ST. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu Rev Pathol. 2012;7:219-45.

2. Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB, Jr., Moine H, Kooy RF, et al. Fragile X syndrome. Nat Rev Dis Primers. 2017;3:17065.

3. Richter JD, Zhao X. The molecular biology of FMRP: new insights into fragile X syndrome. Nat Rev Neurosci. 2021;22:209-22.

4. Dölen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, et al. Correction of fragile X syndrome in mice. Neuron. 2007;56:955-62.

5. Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011;146:247-61.

6. Osterweil EK, Chuang SC, Chubykin AA, Sidorov M, Bianchi R, Wong RK, et al. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron. 2013;77:243-50.

7. Udagawa T, Farny NG, Jakovcevski M, Kaphzan H, Alarcon JM, Anilkumar S, et al. Genetic and acute CPEB1 depletion ameliorate fragile X pathophysiology. Nat Med. 2013;19:1473-7.

8. Feng Y, Absher D, Eberhart DE, Brown V, Malter HE, Warren ST. FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association. Mol Cell. 1997;1:109-18.

9. Stefani G, Fraser CE, Darnell JC, Darnell RB. Fragile X mental retardation protein is associated with translating polyribosomes in neuronal cells. J Neurosci. 2004;24:7272-6.

10. Maurin T, Lebrigand K, Castagnola S, Paquet A, Jarjat M, Popa A, et al. HITS-CLIP in various brain areas reveals new targets and new modalities of RNA binding by fragile X mental retardation protein. Nucleic Acids Res. 2018;46:6344-55.

11. Sawicka K, Hale CR, Park CY, Fak JJ, Gresack JE, Van Driesche SJ, et al. FMRP has a cell-type-specific role in CA1 pyramidal neurons to regulate autism-related transcripts and circadian memory. Elife. 2019;8.

12. Li M, Shin J, Risgaard RD, Parries MJ, Wang J, Chasman D, et al. Identification of FMR1-regulated molecular networks in human neurodevelopment. Genome Res. 2020;30:361-74.

13. El Fatimy R, Davidovic L, Tremblay S, Jaglin X, Dury A, Robert C, et al. Tracking the Fragile X Mental Retardation Protein in a Highly Ordered Neuronal RiboNucleoParticles Population: A Link between Stalled Polyribosomes and RNA Granules. PLoS Genet. 2016;12:e1006192.

14. Das Sharma S, Metz JB, Li H, Hobson BD, Hornstein N, Sulzer D, et al. Widespread Alterations in Translation Elongation in the Brain of Juvenile Fmr1 Knockout Mice. Cell Rep. 2019;26:3313-22 e5.

15. Shah S, Molinaro G, Liu B, Wang R, Huber KM, Richter JD. FMRP Control of Ribosome Translocation Promotes Chromatin Modifications and Alternative Splicing of Neuronal Genes Linked to Autism. Cell Rep. 2020;30:4459-72 e6.

16. Shu H, Donnard E, Liu B, Jung S, Wang R, Richter JD. FMRP links optimal codons to mRNA stability in neurons. Proc Natl Acad Sci U S A. 2020;117:30400-11.

17. Richter JD, Coller J. Pausing on Polyribosomes: Make Way for Elongation in Translational Control. Cell. 2015;163:292-300.

18. Chen E, Sharma MR, Shi X, Agrawal RK, Joseph S. Fragile X mental retardation protein regulates translation by binding directly to the ribosome. Mol Cell. 2014;54:407-17.

19. Korb E, Herre M, Zucker-Scharff I, Gresack J, Allis CD, Darnell RB. Excess Translation of Epigenetic Regulators Contributes to Fragile X Syndrome and Is Alleviated by Brd4 Inhibition. Cell. 2017;170:1209-23 e20.

20. Hale CR, Sawicka K, Mora K, Fak JJ, Kang JJ, Cutrim P, et al. FMRP regulates mRNAs encoding distinct functions in the cell body and dendrites of CA1 pyramidal neurons. Elife. 2021;10:e71892.

21. Schwartz S, Meshorer E, Ast G. Chromatin organization marks exon-intron structure. Nat Struct Mol Biol. 2009;16:990-5.

22. Kolasinska-Zwierz P, Down T, Latorre I, Liu T, Liu XS, Ahringer J. Differential chromatin marking of introns and expressed exons by H3K36me3. Nat Genet. 2009;41:376-81.

23. Kim S, Kim H, Fong N, Erickson B, Bentley DL. Pre-mRNA splicing is a determinant of histone H3K36 methylation. Proc Natl Acad Sci U S A. 2011;108:13564-9.

24. Pradeepa MM, Sutherland HG, Ule J, Grimes GR, Bickmore WA. Psip1/Ledgf p52 binds methylated histone H3K36 and splicing factors and contributes to the regulation of alternative splicing. PLoS Genet. 2012;8:e1002717.

25. Bhattacharya S, Levy MJ, Zhang N, Li H, Florens L, Washburn MP, et al. The methyltransferase SETD2 couples transcription and splicing by engaging mRNA processing factors through its SHI domain. Nat Commun. 2021;12:1443.

26. Shah S, Sharp KJ, Raju Ponny S, Lee J, Watts JK, Berry-Kravis E, et al. Antisense oligonucleotide rescue of CGG expansion-dependent FMR1 mis-splicing in fragile X syndrome restores FMRP. Proc Natl Acad Sci U S A. 2023;120:e2302534120.

27. Akerman M, David-Eden H, Pinter RY, Mandel-Gutfreund Y. A computational approach for genome-wide mapping of splicing factor binding sites. Genome Biol. 2009;10:R30.

28. Sznajder LJ, Michalak M, Taylor K, Cywoniuk P, Kabza M, Wojtkowiak-Szlachcic A, et al. Mechanistic determinants of MBNL activity. Nucleic Acids Res. 2016;44:10326-42.

29. Vuong JK, Lin CH, Zhang M, Chen L, Black DL, Zheng S. PTBP1 and PTBP2 Serve Both Specific and Redundant Functions in Neuronal Pre-mRNA Splicing. Cell Rep. 2016;17:2766-75.

30. Paz I, Kosti I, Ares M, Jr., Cline M, Mandel-Gutfreund Y. RBPmap: a web server for mapping binding sites of RNA-binding proteins. Nucleic Acids Res. 2014;42:W361-7.

31. Terenzi F, Ladd AN. Conserved developmental alternative splicing of muscleblind-like (MBNL) transcripts regulates MBNL localization and activity. RNA Biol. 2010;7:43-55.

32. Gates DP, Coonrod LA, Berglund JA. Autoregulated splicing of muscleblind-like 1 (MBNL1) Pre-mRNA. J Biol Chem. 2011;286:34224-33.

33. Tran H, Gourrier N, Lemercier-Neuillet C, Dhaenens CM, Vautrin A, Fernandez-Gomez FJ, et al. Analysis of exonic regions involved in nuclear localization, splicing activity, and dimerization of Muscleblind-like-1 isoforms. J Biol Chem. 2011;286:16435-46.

34. Kino Y, Washizu C, Kurosawa M, Oma Y, Hattori N, Ishiura S, et al. Nuclear localization of MBNL1: splicing-mediated autoregulation and repression of repeat-derived aberrant proteins. Hum Mol Genet. 2015;24:740-56.

35. Tabaglio T, Low DH, Teo WKL, Goy PA, Cywoniuk P, Wollmann H, et al. MBNL1 alternative splicing isoforms play opposing roles in cancer. Life Sci Alliance. 2018;1:e201800157.

36. Tamanini F, Bontekoe C, Bakker CE, van Unen L, Anar B, Willemsen R, et al. Different targets for the fragile X-related proteins revealed by their distinct nuclear localizations. Hum Mol Genet. 1999;8:863-9.

37. Dury AY, El Fatimy R, Tremblay S, Rose TM, Cote J, De Koninck P, et al. Nuclear Fragile X Mental Retardation Protein is localized to Cajal bodies. PLoS Genet. 2013;9:e1003890.

38. Spector DL, Lamond AI. Nuclear speckles. Cold Spring Harb Perspect Biol. 2011;3(2): a000646.

39. Ilik IA, Malszycki M, Lubke AK, Schade C, Meierhofer D, Aktas T. SON and SRRM2 are essential for nuclear speckle formation. Elife. 2020;9: e60579.

40. Konieczny P, Stepniak-Konieczna E, Sobczak K. MBNL expression in autoregulatory feedback loops. RNA Biol. 2018;15:1-8.

41.Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature. 2010;463:457-63.

42. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, et al. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008;456:470-6.

43. Liu S, Gao Y, Canela-Xandri O, Wang S, Yu Y, Cai W, et al. A multi-tissue atlas of regulatory variants in cattle. Nat Genet. 2022;54:1438-47.

44. López-Martínez A, Soblechero-Martin P, de-la-Puente-Ovejero L, Nogales-Gadea G, Arechavala-Gomeza V. An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I. Genes (Basel). 2020;11: 1109.

45. Tran SS, Jun HI, Bahn JH, Azghadi A, Ramaswami G, Van Nostrand EL, et al. Widespread RNA editing dysregulation in brains from autistic individuals. Nat Neurosci. 2019;22:25-36.

46. Liu B, Li Y, Stackpole EE, Novak A, Gao Y, Zhao Y, et al. Regulatory discrimination of mRNAs by FMRP controls mouse adult neural stem cell differentiation. Proc Natl Acad Sci U S A. 2018;115:E11397-E405.

47. Konieczny P, Stepniak-Konieczna E, Sobczak K. MBNL proteins and their target RNAs, interaction and splicing regulation. Nucleic Acids Res. 2014;42:10873-87.

48. Wang PY, Chang KT, Lin YM, Kuo TY, Wang GS. Ubiquitination of MBNL1 Is Required for Its Cytoplasmic Localization and Function in Promoting Neurite Outgrowth. Cell Rep. 2018;22:2294-306.

49. Kelleher RJ, 3rd, Bear MF. The autistic neuron: troubled translation? Cell. 2008;135:401-6.

50. Huber KM, Klann E, Costa-Mattioli M, Zukin RS. Dysregulation of Mammalian Target of Rapamycin Signaling in Mouse Models of Autism. J Neurosci. 2015;35:13836-42.

51. Bowling H, Bhattacharya A, Zhang G, Alam D, Lebowitz JZ, Bohm-Levine N, et al. Altered steady state and activity-dependent de novo protein expression in fragile X syndrome. Nat Commun. 2019;10:1710.

52. Alpatov R, Lesch BJ, Nakamoto-Kinoshita M, Blanco A, Chen S, Stutzer A, et al. A chromatin-dependent role of the fragile X mental retardation protein FMRP in the DNA damage response. Cell. 2014;157:869-81.

53. Tapial J, Ha KCH, Sterne-Weiler T, Gohr A, Braunschweig U, Hermoso-Pulido A, et al. An atlas of alternative splicing profiles and functional associations reveals new regulatory programs and genes that simultaneously express multiple major isoforms. Genome Res. 2017;27:1759-68.

54. Parras A, Anta H, Santos-Galindo M, Swarup V, Elorza A, Nieto-Gonzalez JL, et al. Autism-like phenotype and risk gene mRNA deadenylation by CPEB4 mis-splicing. Nature. 2018;560:441-6.

55. Huber KM, Kayser MS, Bear MF. Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science. 2000;288:1254-7.

56. Shah S, Richter JD. Do Fragile X Syndrome and Other Intellectual Disorders Converge at Aberrant Pre-mRNA Splicing? Front Psychiatry. 2021;12:715346.

57. Irimia M, Weatheritt RJ, Ellis JD, Parikshak NN, Gonatopoulos-Pournatzis T, Babor M, et al. A highly conserved program of neuronal microexons is misregulated in autistic brains. Cell. 2014;159:1511-23.

58. Li R, Dong Q, Yuan X, Zeng X, Gao Y, Chiao C, et al. Misregulation of Alternative Splicing in a Mouse Model of Rett Syndrome. PLoS Genet. 2016;12:e1006129.

59. Thacker S, Sefyi M, Eng C. Alternative splicing landscape of the neural transcriptome in a cytoplasmic-predominant Pten expression murine model of autism-like Behavior. Transl Psychiatry. 2020;10:380.

60. Gonatopoulos-Pournatzis T, Blencowe BJ. Microexons: at the nexus of nervous system development, behaviour and autism spectrum disorder. Curr Opin Genet Dev. 2020;65:22-33.

61. Yukselen O, Turkyilmaz O, Ozturk AR, Garber M, Kucukural A. DolphinNext: a distributed data processing platform for high throughput genomics. BMC Genomics. 2020;21:310.

62. Shen S, Park JW, Lu ZX, Lin L, Henry MD, Wu YN, et al. rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. Proc Natl Acad Sci U S A. 2014;111:E5593-601.

63. Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2:100141.

64. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284-7

65. Amand J, Fehlmann T, Backes C, Keller A. DynaVenn: web-based computation of the most significant overlap between ordered sets. BMC Bioinformatics. 2019;20:743.

Supporting information captions

S1. Gene Ontology (GO) terms

(A) GO terms for skipped/included exons in *Fmr1* KO CTX and HC.

(B) Volcano plots of RNAs up or down regulated ($log_2FC > 0.2$ or < -0.2, FDR<0.05, n=3) in *Fmr1* KO liver (LV), muscle (MU), and testis (TE).

(C) *Fmr1* RNA levels (TPM) in brain regions and peripheral tissues.

(D-F) GO terms of RNAs up or down regulated in *Fmr1* KO LV, MU, TE.

(G) GO terms for skipped/included exons in *Fmr1* KO LV and MU.

S2.

(A) GO terms for RNAs that display exon skipping in *Fmr1*-depleted N2A cells.

(B) DNA sequence analysis of parental N2A cells (top) and Fmr1-depleted cells (bottom). The shaded portion corresponds the amino acid sequences shown in **Figure 2**. The red box indicates the nucleotides depleted by CRISPR/Cas9 editing. Following editing, the TAG at the right of the shaded box becomes a premature stop codon, leading to nonsense mediated mRNA decay and loss of FMRP expression.

(C) Mean fluorescence intensity (MFI) of mCherry/GFP was evaluated by flow cytometry in control cells transfected with a splicing reporter with an MBNL1 binding site deletion (UGCUGC).

S3. Efficacy of splicing factor depletion and determination of skipping of control exons.

(A-H) Efficacy of *Fmr1* and splicing factor depletion by siRNAs. *$p < 0.05$; **$p < 0.01$; ***$p < 0.001$; ****$p < 0.0001$ (n=3).

(I-T) Determination of skipping of constitutive exons *Mapt* exon 15, *App* exon 2, and *Tnik* exon 25 following *Fmr1* and splicing factor depletion. *$p < 0.05$; **$p < 0.01$ (n=3).

S4. MBNL1 binding sites in exons regulated by FMRP.

Analysis of MBNL1 binding sites was conducted using data from MBNL1 RIP-seq, with binding sites highlighted in blue, and CLIP-seq, with binding sites indicated in orange [28, 29]. These binding sites were analyzed in exons located near *Fmr1*-regulated splicing events that display alterations which are shaded in grey.

S5. PTBP1 binding Sites in Exons Regulated by FMRP.

Analysis of PTBP1 binding sites using 6-mer binding motifs TCTCTC and CTCTCT. The binding sites are highlighted in red and green, respectively. These binding sites were analyzed in exons located near *Fmr1*-regulated splicing events that display alterations which are shaded in grey.

S6. Western blot for SETD2 and H3K36me3 in control and *Fmr1* depleted N2A cells.

(A) Western blot for SETD2, H3K36me3, H3, and FMRP in nuclear extracts of control and *Fmr1* deficient N2A cells. LaminB1 is used as a loading control.

(B) RT-PCR for *Mbnl2* exon 5 splicing in control and *Fmr1* deficient N2A cells and WT and *Fmr1* KO HC. Band intensity of exon 5 is quantified and mean ± S.D is shown (Student's t-test, *$p < 0.05$). The constitutive exon 9 was amplified to compare total *Mbnl2* RNA expression.

S7. Efficacy of FMRP and MBNL1 depletion and ectopic expression.

(A) Western blot for FMRP and MBNL1. GAPDH is used as a loading control.

S8. Splicing events mediated by MBNL1 isoforms.

(A) Violin plots showing the distribution of delta PSI in siFmr1+nMBNL1 and siMbnl1+cMBNL1. The solid line is the median and the dashed lines are quartiles. P-value < 0.05, |delta PSI| > 0.05.

(B) PSI of *Mbnl1* exon 5 in all experimental groups.

(C) Venn diagram comparing spliced exon events in siFmr1 and siMbnl1 cells.

S9. FMRP-Mediated Regulation of RNA Splicing

(A) Volcano plots showing the differential expression of RNAs associated with RNA splicing upon *Fmr1* depletion. $Log_2FC > 0.2$ or < -0.2, FDR <0.05, n=3.

(B) Volcano plots showing the AS events involved in RNA splicing upon *Fmr1* depletion. P-value < 0.05, |delta PSI| > 0.05.



AS type	HC		CTX		CB	
	Events	Genes	Events	Genes	Events	Genes
SE	328	293	387	346	359	316
MXE	55	51	58	48	50	50
A3SS	79	79	121	116	77	76
A5SS	73	71	61	59	62	58
RI	0	0	0	0	0	0
Total	535	494	627	569	548	500

AS type	LV		MU		TE	
	Events	Genes	Events	Genes	Events	Genes
SE	761	674	956	768	919	803
MXE	341	293	214	188	856	654
A3SS	129	118	122	116	126	121
A5SS	86	78	108	94	112	105
RI	18	18	21	21	16	15
Total	1335	1181	1421	1187	2029	1698

	CTX (346)	CB (316)	LV (674)	MU (768)	TE (803)
HC (293)	59 **	53 *	63 ***	80 *	62
CTX (346)		51	67 **	80 *	73 **
CB (316)			62 *	92 *	80 *
LV (674)				172 **	133 *
MU (768)					133 *





AS type	N2A	
	Events	Genes
SE	1378	1124
MXE	457	406
A3SS	116	112
A5SS	112	103
RI	15	15
Total	2078	1760



Gene	Delta PSI	P-Value
Mapt	0.134	0.003
Tnik	0.235	0.017
Wnk1	0.366	0.001
App	-0.096	0.0003
Ski	-0.165	0.048
Os9	-0.113	2.9E-08













E

		Inclusion/Skipping		
		Mapt Exon 4	*Tnik* Exon 21	*App* Exon 8
Single knockdown	*Fmr1*	1.70	1.60	0.59
	Mbnl1	2.32	1.20	0.66
	Ptbp1	2.57	9.16	0.48
	hnRNPF	1.10	1.47	0.68
	hnRNPQ	1.07	0.90	0.95
Double knockdown	*Fmr1/Mbnl1*	3.84	1.68	0.57
	Fmr1/Ptbp1	1.59	9.99	0.49
	Fmr1/hnRNPF	1.77	2.03	0.47
	Fmr1/hnRNPQ	1.25	0.97	0.71


A
Mbnl1
Ptbp1
hnRNPF
hnRNPQ
Srsf5
Relative expression
Input
Precleared
IgG
FMRP
*
****
B
siNT
siFmr1
FMRP
MBNL1
hnRNPQ
PTBP1
hnRNPF
Tubulin
GAPDH
70
40
70
55
55
55
35
Total MBNL1/TUB
Upper MBNL1/TUB
Lower MBNL1/TUB
PTBP1/GAPDH
Total hnRNPQ/GAPDH
Upper hnRNPQ/GAPDH
Lower hnRNPQ/GAPDH
hnRNPF/GAPDH
Band intensity (relative ratio)
***
**
ns
C
MG132 (10μM, h)
0 1 2 4 0 1 2 4
MBNL1
FMRP
GAPDH
Lactacystin (10μM, h)
0 1 2 4 6 0 1 2 4 6
siNT
siFmr1


A
Mbnl1 isoforms
Exon number
Constitutive exon
Alternative exon
1 1b 2 3 4 5 6 7 8 9 10
B
siNT
siFmr1
+ Ex 5
– Ex 5
+ Ex 7
– Ex 7
Ex 10
Mbnl1 Exon 5
Mbnl1 Exon 7
Inclusion/Skipping (Relative band intensity)
**
ns
siNT siFmr1
C
Cytoplasmic fraction
Nuclear fraction
siNT
siFmr1
40
70
55
MBNL1
Lamin B1
Tubulin
Cytoplasmic fraction
Nuclear fraction
Upper MBNL1/Tubulin
Lower MBNL1/Tubulin
Upper MBNL1/LaminB1
Lower MBNL1/LaminB1
Band intensity (relative ratio)
*
**
D
FMRP
MBNL1
Nuclei
MBNL1 Nuclei
siNT
siFmr1
MBNL1 Nucleus/Cytoplasm (Fluorescence Intensity Ratio)
E
DAPI
sc-35
FMRP
FMRP Sc-35
FMRP Sc-35 DAPI

Alternative splicing of *Mbnl1* RNA in FMRP-deficient cells and tissues.

Exon number	Domain, function	Species	Sample	Category	Delta PSI	P-value	Reference
Exon 1	ZnF domain that important for RNA binding and splicing activity [33]	Mouse	LV	SE	-0.146	0.01	This study
Exon 4/Exon 5	ZnF domain that important for RNA binding and splicing activity/NLS [33, 44]	Human	Post-mortem cortex	MXE	0.21	0.01	[45]
Exon 5	NLS [33, 44]	Mouse	LV	SE	-0.3	0.04	This study
Exon 5	NLS [33, 44]	Mouse	MU	SE	0.174	0.0005	This study
Exon 5	NLS [33, 44]	Mouse	TE	SE	0.191	0.04	This study
Exon 5	NLS [33, 44]	Mouse	N2A	SE	-0.228	4.54-E06	This study
Exon 6	Splicing regulatory domain, encode for bipartite NLS [33]	Mouse	Adult NSC	SE	0.33	0.001	[46]
Exon 6	Splicing regulatory domain, encode for bipartite NLS [33]	Mouse	LV	A3SS	-0.082	0.005	This study
Exon 7	Enhances MBNL1 self-dimerization [44, 47]	Mouse	CB	SE	0.093	0.03	This study
Exon 7	Enhances MBNL1 self-dimerization [44, 47]	Mouse	MU	SE	0.044	0.03	This study
Exon 7	Enhances MBNL1 self-dimerization [44, 47]	Mouse	TE	SE	-0.332	0.0002	This study
Exon 7/Exon 8	Enhances MBNL1 self-dimerization [44, 47]	Mouse	MU	MXE	0.051	0.0008	This study
Exon 8	Unknown	Mouse	MU	SE	-0.101	0.0001	This study

A

Ct	Mbnl1	Mbnl2	Gapdh
	21.71	23.04	15.65
	22.08	23.30	15.67
	22.14	23.27	15.87
Average	21.97	23.20	15.73

Ct	Ptbp1	Ptbp2	Gapdh
	20.02	23.31	16.27
	19.66	22.48	16.01
	19.68	22.30	15.93
Average	19.79	22.70	16.07

B



C



D



E





	Mbnl1 Ex5 Inclusion/Skipping
siNT	1.00
siFmr1	0.52
siMbnl1	1.88
siFmr1 + nMBNL1	37.23
siMbnl1 + cMBNL1	0.002

A

AS type	siFmr1		siMbnl1		siFmr1+nMBNL1		siMbnl1+cMBNL1	
	Events	Genes	Events	Genes	Events	Genes	Events	Genes
SE	3414	2312	3995	2592	4425	2810	4653	2860
MXE	3414	2309	3925	2548	4586	2855	5354	3161
A3SS	219	199	237	214	257	230	241	216
A5SS	189	162	227	192	481	355	199	180
RI	74	72	76	74	85	80	76	70
Total	7310	5054	8460	5620	9834	6330	10523	6487





	Fmr1
CTX	3232
HC	2770
CB	3781
LV	340
MU	207
TE	513


A
SE N2a Inclusion/Skipping
Covalent chromatin modification
Regulation of cellular amide metabolic process
Regulation of translation
Peptidyl-lysine modification
Dendrite development
Regulation of small GTPase mediated signal transduction
Protein acylation
Microtubule-based transport
Cytoskeleton-dependent intracellular transport
Transport along microtubule
0.025
0.030
0.035
0.040
GeneRatio
p.adjust
0.0010
0.0015
0.0020
0.0025
0.0030
Count
25
30
35
40


C
Control
ns
mCherry/GFP (MFI)
0
1
2
3
4
pFlare-Mapt E4 + –
pFlare-Mapt E4 – +
ΔTGCTGC


B
Parental N2a
GCAACCAGAGAGACAGATTCCATTCCATGATGTGAGATTCCCACCACCTGTAGGTTATAATAAAGATATAAACGA
Fmr1 KO N2a
GCAACCAGAGAGACAGATTCCATTCCATGATGTGAGATTCCTGTAGGTTATAATAAAGATATAAACGA


A
Fmr1
Relative expression
siNT
siFmr1
siMbnl1
B
Mbnl1
C
Fmr1
siPtbp1
D
Ptbp1
E
Fmr1
sihnRNPF
F
hnRNPF
G
Fmr1
sihnRNPQ
H
hnRNPQ
I
Mapt Exon 15
J
Mapt Exon 15
Inclusion/Skipping
K
Mapt Exon 15
L
Mapt Exon 15
M
App Exon 2
N
App Exon 2
O
App Exon 2
P
App Exon 2
Q
Tnik Exon 25
R
Tnik Exon 25
S
Tnik Exon 25
T
Tnik Exon 25

A

Mapt

Exon 4
CCGAAGAAGCAGGCATCGGAGACACCCCGAACCAGGAGGACCAAGCCGCTGGGCATGTGACTCAAG
MBNL1 binding site (RIP-seq)
AGGAGGACCAAGCCGCTGGGCAT

CTTCTGGGTACACACCATCAAAAATAATCTCTCCCTGAACCCCAGTCCTCCCAAAGTGCTGGCCAGAGCAGGCAGTGCCACTGTGACTCATCTGTGAGCC
CCTAAGTTCTGGCATCTTTGTGGAGCCAGGCAAGGCATCAGGACCCTGGACCCCTATGGAAAAGCTCTTTCCTCCTCGGTCGCAGTCACCTGGAAGGCA
CGTGAGTGCTATGGATTTTGTTTAGGCACATGTCATCACCACTGTCCCTAGCCGTGGCCATTGCAGAGGAGCAAAACACTGCAGCTGGCCCTGCAGGGT
GCCCATGTGCACACACACGAGGAACACAGGTACAGAGAGCATGGGTTGCAACAAGAAATAACAGTCTCCCTTCTGTCCTCTCCCTTTGCTGCCTCGGAC
CAGCCGAAGAAGCAGGCATCGGAGACACCCCGAACCAGGAGGACCAAGCCGCTGGGCATGTGACTCAAGGTCAGTGGCCCAAATCGACTTTGGGACT
CAGATTGGGAGGAGGGAGATGGGAGCACTCAGTGGGCTCTACCTTGAAAAGACATCTTAGCGCCAGGTCCTAGGGCACAAGTTCAGGAGACCCGAAGG
AGTTGCCAATATCAAAGTTGGCCTCTGTAGACACAGACAGCGTTTTCTTATACCATCCTGGTTCAGGTCATGCCTAGCCCGGGGATGAGGCCAGTGGGTG
ACGCTCCCACAGGGTGCCCTGTGGCCTGTCAATCACATCACCAATGCACTTGTCATTCGAACTTCCTTCTCTGCAGTCTTCACACCTTATTAGGATTTTCTT
CTCAGGAACTAAATTGTTGTGTTCAGGAGAAGTAGCT

App

Exon 8
CAACCCAAAGTTTACTCAAGACTACCAGTGAACCTCTTCCCCAAGATCCTGATAAAC
Mbnl1 binding site (CLIP-seq)
GATTATCCTGGAGGGGATGGGGGGATCCTAACCTCA

TCTCGTTTTCTCCATAGCAACCCAAAGTTTACTCAAGACTACCAGTGAACCTCTTCCCCAAGATCCTGATAAACGTATGTTGTCACTGACTTGGGGGAGGG
GCAAGGGGAAGACTATGTTGCATGACTGAATGTGTCCTTCCCTTGCATCATCTGCTTGGCATGGGTTTTGTGTGATTATTGACCAGGAACCTTTTGATAGAT
ACTATTTTCCCATTGTCTTGCGTGTCATTTCATCCGGTTTTTACTAGGCAACTTCAGATGTTGGGCAGAGAGCATCTACTTAAACCATTTACACTTCTGAACA
AATTCCTTTCTGATTTGTGTTGTTCTGTGAAATACCACACATAGAGTATTTCTTGATTTGGCAGAACTTTTTTTTTTAATTTCCCGAAAGCTGTCAACATGCCA
TAATTTAATGAAATCATATTTGATAGTACAGGTAACCCCCTCCCTAAAAATGTAATATTGCTTATTCAAGACAATTTTGTGTGCACATTTCAAGGTTCCTGTGTT
AAATGATAACTGTGCAGCATTGGGAGGTGAAAGGTGAGCCACATAGATTTCAGGACTCCCCTCCTCCCCCTCCCAGAGTGCACACTGGTTGGTGTGCTAT
CAGGTCTTCCACTTAGGGAACTTAATGGAATTTCCTATAAAAAGACATTGCTTCAACCATATAATATACTCTTGGTCTTAACAGCGTCTTGCTTTCTGGTTGCC
CAATCAGTCTAATTTCATTTTCAAATGTCATATCTAACACATCCATATTCGCTTTTAAAATTCAGTCTGTATTTAGAAATGGATCCCCCCTCTCCAGGGATGGTC
TATATTGTTGGTACTTACTGAGGCTTGAAGAGGAAACCCAATTTCAGTTGGAAATGAGATGATTAAAATTCGCCTTTGTCACGATTATCCTGGAGGGGATGG
GGGGATCCTAACCTCAAAACTAATAAGAAAATGATTTTTAAAAAATGTAGTGTAGATGATT

Ski

Exon 2
GTCTCAGAGCCCCCAGCTTCCATAAGACCCAAAACAGACGACACTTCCTCACAGTCCCCTGCGTCTTCTGAGAAGGACAAGCAGTCCACTTGGCTGCGG
ACCTTGGCTGGTTCCTCCAATAAG
Mbnl1 binding site (CLIP-seq)
ATAAGGTGCTATGTGGGAACCTGTCTGGGGTCTTTG
MBNL1 binding site (RIP-seq)
CACTTGGCTGCGGACCTTGGCTGGTTCCTCC

AAAGTAGTGTGGACTGAAGGCAAAGAAACTCAGGTCAAAGCACAGAGCCCGCTGCAGCTGTGAGTGAGGTCACCTCACTGCAGCCCACAGCAGCATAG
CATTTCTCTGTCTCATGTGACGTCCTCGTCCCTTAGTAGACACATCAGGCTTCCCTTTCTGCACAGGGTCAAGGGCACACTGTGTTTGTAGCTCCGTACAT
TTGGGTCCCCGGGGCTCCTTCATAGCTGTGGAGTTACGATGATCCAGTGGGGAGCTTGATACCATGGGGCTGGTAGGAAGACCTGCCTGGGCCCAGGG
ATCCCAACCGGGGCCTTTTGTATTGATCACAGGTCTCAGAGCCCCCAGCTTCCATAAGACCCAAAACAGACGACACTTCCTCACAGTCCCCTGCGTCTTC
TGAGAAGGACAAGCAGTCCACTTGGCTGCGGACCTTGGCTGGTTCCTCCAATAAGGTGCTATGTGGGAACCTGTCTGGGGTCTTTGGGGGTGGTGCAA
GGCTCTTCTTAGAGCCAACTCTGTGCCTCTACTCAGCCTCAGGGGCATAAAGTGGCGTGTTTTTCTGTAATCACTCACATAGATTTTCTTGACAGAGCCTC
GGCTGCACTCACCCTCGCCAGCGCCTTTCTGCTTTCCGGCCCTGGTCCCCTGCAGTGTCTGCGAGTGAGAAAGAGACGTCCCCACACCTCCCAGCTTT
GATTCGAGACAGGTGAGTGGGGAATAGACAGGACTGAGCTCTGGTTTAGCAGGCTTTGATGGTGTTGGTGCCTTTAGTCTTAGGATAAACTGCCTAGACC
ATTAAAGTCTTTGATGAAGGTGCTGAGTTCACAGACAGTATTAAGAATTAGCCTCTAGCCGGGCAAGGTGGCGCACACCTTTAATTCCAGCACTCGGGAGA
CAAAGGCAGATGGATTTCTGAGTTGGAGGCCAGCCTGGTCTACAAAGTGAGCTCCAGGACAGCCAGGGCTATACAG

Tnik

Exon 20 (Upstream exon of target exon)
CCAACAGTAAGTCCGAAGGATCACCCGTGCTCCCCCATGAGCCTTCCAAGGTGAAACCAGAAGAATCCAGAGACATCACACGGCCCAGTCGGCCAGCT
MBNL1 binding site (RIP-seq)
CCAGAAGAATCCAGAGACATCACACGGCCCAGTCGGCCAGCTGT

AAGAACATGGAGCCATAGTACTATGTGGGAGCAAGGATGAATGGCAGTGATTGACAGAATAAGCGTTTGGTGTTGTGCCTAAGACACAGTAAGCTCTTGGT
AAACGGTAGTGACAAGTACAGTGCTTGCTGAAGAGTCTCAGTTTTACTGTTGACTTCTCGGTGGCAGGCCTACATTGTCGACCTCTGTTTTCTGAGCATTT
ATTATTTTTCCATGGATACATATAGGTTTGCCTCGTGAGTTGGCTTTCCTTAGTCACTCCCTCAGAATGCGAGACAGGCTTTTCTAATAGCTGTGTTCCTGTT
CTCTCCTCTAGCCAACAGTAAGTCCGAAGGATCACCCGTGCTCCCCCATGAGCCTTCCAAGGTGAAACCAGAAGAATCCAGAGACATCACACGGCCCAG
TCGGCCAGCTGTGAGTGCTTTTCTTTCTACGGATTTGGAACTCTTCCTTTACCTGGGGATCCCAGGATGATGTAGTTAGGGTTGCCTTTATGACTCAAAGC
AAAAGTTGGGAGATGAATAAGAGCACTGTGTGCTAAACACATCTAGAAGACAGTCATGCATGACGAGGAAGGTACGGAGTGGATTTTAGGCTGCTTCCTC
TGCTCTGAGGGCTTTTGTTGCTCATCACCATTCTAGGAAGAAGGAAAGAAATTAGCTCACACCATCGCACAATATTTGCTCATTACTTTGACAAGAAAAGAT
GTTAAAAGTAGCAGTTAGGAAACCTGGGCTGTTCCTATGAGTTGCTTCATCCAGACTCCACACTGGCTT

A

Mapt

Exon 4
CCGAAGAAGCAGGCATCGGAGACACCCCGAACCAGGAGGACCAAGCCGCTGGGCATGTGACTCAAG
Ptbp1 binding site
TCTCTC/CTCTCT

TTTGAGGTGACTGTTGGCTTCTTAAATAAAACCCAAAGGCCCTGAAAAGCTATCCATTGGCCCTGTTGGCCTCCCTCCAGCCAGGTAGTGCTGGGGTTTT
TTTTTTTGTTGTTGTTTTGTTTCGTTTTTTTTAAATGTATTTATTATATGTATGTGAATACACTGTAGCTGTCTTCAGACACATCAGAAGAAAGCATCAGATCTCA
TTACAGATGGTTGTGAGCCGCCATGTGGTTGCTGGGAATTGAACTCGAGACCTTTGGAAGGGCAGTCAGTATTTTTAACCGCTTAGCCATGAGCCATCTCTC
CCAGTCCCAGGTAGTGCTGTTTTTAGGAGTGATGTGTGGCAAGGTTTAAAGAGAAGGAGCATAGCAGCTTGGAGCATCTCCTTCCTGTCTTCAGGCCTTC
ACCATCCTCCTACAAGACAAACCCTAGTCCCTCCTTAAGGTTTCCAATAATAGAGGCTCAGAGAAGCTGGACAGGGGATGGCTTCTGGGTACACACCATC
AAAAATAATCTCTCCCTGAACCCCAGTCCTCCCAAAGTGCTGGCCAGAGCAGGCAGTGCCACTGTGACTCATCTGTGAGCCCCTAAGTTCTGGCATCTTT
GTGGAGCCAGGCAAGGCATCAGGACCCTGGACCCCTATGGAAAAGCTCTTTCCTCCTCGGTCGCAGTCACCTGGAAGGCACGTGAGTGCTATGGATTTT
GTTTAGGCACATGTCATCACCACTGTCCCTAGCCGTGGCCATTGCAGAGGAGCAAAACACTGCAGCTGGCCCTGCAGGGTGCCCATGTGCACACACAC
GAGGAACACAGGTACAGAGAGCATGGGTTGCAACAAGAAATAACAGTCTCCCTTCTGTCCTCTCCCTTTGCTGCCTCGGACCAGCCGAAGAAGCAGGCA
TCGGAGACACCCCGAACCAGGAGGACCAAGCCGCTGGGCATGTGACTCAAGGTCAGTGGCCCAAATCGACTTTGGGACTCAGATTGGGAGGAGGGAG
ATGGGAGCACTCAGTGGGCTCACCTTGAAAAGACATCTTAGCGCCAGGTCCTAGGGCACAAGTTCAGGAGACCCGAAGGAGTTGCCAATATCAAAGTT
GGCCTCTGTAGACACAGACAGCGTTTTCTTATACCATCCTGGTTCAGGTCATGCCTAGCCCGGGGATGAGGCCAGTGGGTGACGCTCCCACAGGGTGCC
CTGTGGCCTGTCAATCACATCACCAATGCACTTGTCATTCGAACTTCCTTCTCTGCAGTCTTCACACCTTATTAGGATTTTCTTCTCAGGAACTAAATTGTTG
TGTTCAGGAGAAGTAGCTTTCTGCAGCTGTGGGTCACAGATACGCTTTAAAAAAAAAAAAAAAATTTTTTTAACCTTAGAGAGTCTTAGGAACTGGAGATCT
CTGACATAGAGCAAGAGCTGGCTTTGTTTTCTTCCATTTTTCTGGATAAATGAACTTGAGAGTGTCCTGTGTAGCAGCCAGACATACAGATAGATGGCAGA
GGAGCTGGGGGGTGGTGTCCTTTGCTCGATAAGGTGACAAGGGATTTGTCTTTTGTTTAGCGGTGCTGGCCGCCTGTAAAGGGCTCTGCCTCACTGACC
TCAAGAGTTAATCATCCTTTAGGTAACTTGGACACTAGACTGCTGAGGAGGACTTGGGGGAGACTTTTGGTCATGGTCCTGTGTTTACCCTGACATTTGCC
TTACTGCCCCTCCACCACTCCCAGAGAGTCTGCACTTAAAAAACAGTTTTGTTTTGAGATAAGATCCTCCCAGCCCCAGCTGGCCTCCATTTGTATTCAAG
GATGACCTTGATCTTTGACCCTCCTACTTCCACCTTCTTGGGAATGCTGTGGTTAGAGGCATGTGCTGCCACACCCCGTTTACAAGATTCTGTGACCAAAC
TCAGAGCTTCTTGTGGACTGGGTAAGCGTTAACCGAGCTGCATCCTGGCC

App

Exon 8
CAACCCAAAGTTTACTCAAGACTACCAGTGAACCTCTTCCCCAAGATCCTGATAAAC

Ptbp1 binding site
TCTCTC/CTCTCT

CAGTGTCTCTCAGGAAACATCCAACTGTCTCTACTGTGGGAGATAATGATGTGAAGTCCTGATGACTTCAGTGTAAAATGAAGTATTCCCCGCAGAGAGTC
AGTCCCCAAGAAGCCATGTCTCAGATATATGGAATATCTGCTTCTATTAGTAGCCTTTCAAGCAAAGTCCTTAGTTGTATTTGTTTATTCTTGATCACAAGTTG
GCTATATGAATTATTCAAGGGTCTTAGTGACAGTGCATGCCTTTCTTGAGAGATTCTTGCATTTTAATTCTTGAATTTGCAGGGAGACATATCCCTTCCCTTTC
CCTGGATATCTGGGAACATTCTGGCAATTTTCCAACCAAATCCCAGAACCAAGCAAAACAAAGACTTGCTCTCTTAAGACCTCACACTGTGAGGTAGCTAA
TATCTGTTTGGGACCTAGAAAGGTCTTATTGGTCTCCTAGGAGATAACTCCACTTAAGTACTCTGAGGAAACTAGTAGTGGAGAGGCTCTGACTTCAATTGG
ATGATTGTAGCTCCTAGTTGAAGATACCCAAGCTCATTTTCACCTAGAGGTTAATTGGGTTAGATAACTGAAACACAATAAAGGAGTCTGGTGCCTGGAGCC
TTTGGAACAAAGGGCCTTTGTTACCTCGGCTCTAAAGGGTTTAGCTGCTAGGTCAGGATTTCCTGGCAAAGTTCTCAGGTTTCCCCCCCTTTCCCTAAGGT
AGGGTTAGTTTCTGGAATATCATATTCTAGCGATCAGGAAGTTTGCTTTATATTATTAGCAGAGAACAATTCAACTCAAGTTTTGGACACTGTCTTCTTACCCA
CCCTAGTGTAAACCCCCCTCATCTCCCTTCCACTTGATTACTCTGTGCAGGGAGTATAAAACATTATATACCTTCACCAGGGGTTGGAGCATGCATACACTT
TATAGATGGATTTGTAAAAATCCAGTGCCTTCAACAGGGTCTTATGAGAGAAGGTCTGTAGTCCTGATTTCATTTTTACAGAGTCGGGTTACAAGGTATCAA
GGAAGCAAAGGCACAGCTGGGTACCAGACTCTGGTCTGATTCTCAGAACCTTTGGAGGAATAAGGCAGGGGATGGGAAGGCTGGAGAGATGCTTCAGT
CTTCTTTTAAAAAAAAAGAAAGAGAAAATTTCAATAAAAGCAAGAGAACCAGCGTTCAGGTCTCCAGCACCTGTTGAGCGTGGTATTGTTAGCACTTAGAA
GGCAGGGACAGGAGCATCCCTGGGGCTTGCTAGGCAGCCACTGTAGCCAACCAGCAAGCTCCATGTTCACTGAGAAACTTTGTCTCAAACAATATGGCG
AGCAATGGTTGGAAAAGATCTATCTGCTCTCCACACGCATGAATGTGTAACCCTGTGCACATAAGCATTACAAACACATACACTACGCACAGTAATACAACT
TTTAAAAGAAGGAAAGGGAAGAATAGGGTTGAAGGTCAGGTTAGACGGGTGGATAGTGAAGAATGGAAGCCTCATCACATATCTGAGCCAGACCTCAGAA
GCGTCCCCGTGAACAAGTGACATATGCGGAGCTACTGCTGAGGAAGGCGCAGAGAGAAATGAGGGTCATTGGTGCTAATGAGGGAAAAGAGACCCCTAA
GTCCTCCTGTAGATTTCCCAGTGTCCTGTCAGTGGCAGAATGGGCAGCAATTTCACAATACTGATCTTTACTGGTAACAAATCTCACCTGCATTTCCTTGGT
TCTTTGTTTAGGTTTTAATTTTAGTTTCATGATTTCCCTCCCAGCCCTCAATTTTGTTTGATTGCTTTTGAGTCCTGTGGGTGTGTTTCTGCCATCATTCCCAC
CTTTCTGTTGTTGGGGGTTTTTTTTTGTTTGTTTGTTTGTTTTGTTTTGTTTTGTTTTTAGTTATGTTCTCTCGTTTTCTCCATAGCAACCCAAAGTTTAC
TCAAGACTACCAGTGAACCTCTTCCCCAAGATCCTGATAAACGTATGTTGTCACTGACTTGGGGGAGGGGCAAGGGGAAGACTATGTTGCATGACTGAAT
GTGTCCTTCCCTTGCATCATCTGCTTGGCATGGGTTTTGTGTGATTATTGACCAGGAACCTTTTGATAGATACTATTTTCCCATTGTCTTGCGTGTCATTTCA
TCCGGTTTTTACTAGGCAACTTCAGATGTTGGGCAGAGAGCATCTACTTAAACCATTTACACTTCTGAACAAATTCCTTTCTGATTTGTGTTGTTCTGTGAAA
TACCACACATAGAGTATTTCTTGATTTGGCAGAACTTTTTTTTTTAATTTCCCGAAAGCTGTCAACATGCCATAATTTAATGAAATCATATTTGATAGTACAGGT
AACCCCCTCCCTAAAAATGTAATATTGCTTATTCAAGACAATTTTGTGTGCACATTTCAAGGTTCCTGTGTTAAATGATAACTGTGCAGCATTGGGAGGTGAA
AGGTGAGCCACATAGATTTCAGGACTCCCCTCCTCCCCCTCCCAGAGTGCACACTGGTTGGTGTGCTATCAGGTCTTCCACTTAGGGAACTTAATGGAAT
TTCCTATAAAAAGACATTGCTTCAACCATATAATATACTCTTGGTCTTAACAGCGTCTTGCTTTCTGGTTGCCCAATCAGTCTAATTTCATTTTCAAATGTCATA
TCTAACACATCCATATTCGCTTTTAAAATTCAGTCTGTATTTAGAAATGGATCCCCCCTCTCCAGGGATGGTCTATATTGTTGGTACTTACTGAGGCTTGAAGA
GGAAACCCAATTTCAGTTGGAAATGAGATGATTAAAATTCGCCTTTGTCACGATTATCCTGGAGGGGATGGGGGGATCCTAACCTCAAAACTAATAAGAAAA
TGATTTTTAAAAAATGTAGTGTAGATGATTACATCATCCTATACTGTTATTCTTCAGGGGCCTCCATAAGATATTACTGTTAATTCAAATAATGGGATGATATTTG
AAAGATGTGGGTTTTTTTATTGACACAATAAGCCCATGTCCTGATATTGTGAAATTGTTCCTCTAAAACCTTAAGTCTGGCAAGTGGGTGGTAGAGGACTAG
GGAAAGTCTCCGAGCGTCACACCCAAAGACTAGGAAAACATCATTTGTGTGTGTGTCGCGTTGTTCCCAGGGTTTTCAAAGATTGCAGATCTCCTTCTGA
CACACTTGTGTACCTTTTCCTTGCATCTTTGGTGCCTATGAGAAAATCCGAGGCCTAACGCTCTCTGTGCGTTGTCTGCAGGCATCAAACACCAGAGGGC
CGTGTCTGAAACCTAAGGGCACTCTGGCTGGGCTCCACACCAAATGGCTCCACACTGGGTTCTGACATTTTCTAGGTTAGACAGTTTCCAAGGTTCAGAA
AGCACATTTTCAAAAAATATAAGAAACCACACAAAACTGGAAAATGCTAACATACCTCCCCAAC

B

Ski

Exon 2
GTCTCAGAGCCCCCAGCTTCCATAAGACCCAAAACAGACGACACTTCCTCACAGTCCCCTGCGTCTTCTGAGAAGGACAAGCAGTCCACTTGGCTGCGG
ACCTTGGCTGGTTCCTCCAATAAG

Ptbp1 binding site
TCTCTC/CTCTCT

AGCACGTGCACTGCTCACTACCTGGGCCTTGGTGAAGGCCTCCAATGGGGTGGATCATCTCTCCTCTCCAGGTTTCATGGAAGGAAACCTGTCAAGCTG
TTACCTTGGCTGCCTTCTTCCTCATTGCCTCTTCAAGGAAGGCAAGGCCAGTTTTATGATAAGTTGTTTCCCCCAAGTATTCTAGAGAAGAGCCTTGTTCTT
CTGTAGACCAGAAGCCTCACTTTGGCTGCATCCCTCCCATCACACCCAAGGTAACTCCCCCTTTAAAAGGAGGCTGTGTGTGGGGCCAAGGTGTAAGCT
CTGCTATGTCTGCCTTGCGGTCCATGTCATCTACTTAGACCCTAGCTGAGGGACAGTAGCTTAGCGTCTGTAGGCTTAGCTGCTGAGGAAGAGGCCCACG
GATTGTTCTGCACAGGGAATGTCGGTGCGTGTGTGACATGTGACATTTATTTAGGGGGAGGGCCATTGGATTTCACGTACAGACTGGCTCAGGTGTGTAT
CACTTAATGCTGGATGTCAAAATAGACCATGGCTGGTGCCTGAGAAAAGTTAAGGTACTGGGTGGCTTCTGTAAGCTGACAGCAAAGGCAGTGTGGTGAC
ACCTGGTTAAAGCTGTTTTGTGAGGTGTGTCATGATCCTTCAAGCTGAGTATTTCCTTCCTCTGGGGAGAGGGTAACTGCAGTGCTCTCTAATGACGCAGT
GATAAAGGCCACCCAGAGGGTAGCCCAGCCCTCCCAGGCTCCTTACAGGCTTTAATACAGCTGGTTGTTGGATCACACATGAGCCTGAAGTCATTGCTGC
TGGGTCATTTAGCCCATTCCTGACATGGTCCTAGAGTGGGACTGGTCCCGTCCAGCCTTCTTAGCATCATAGCTGCGTTCTAAAGTAGTGTGGACTGAAG
GCAAAGAAACTCAGGTCAAAGCACAGAGCCCGCTGCAGCTGTGAGTGAGGTCACCTCACTGCAGCCCACAGCAGCATAGCATTTCTCTGTCTCATGTGA
CGTCCTCGTCCCTTAGTAGACACATCAGGCTTCCCTTTCTGCACAGGGTCAAGGGCACACTGTGTTTGTAGCTCCGTACATTTGGGTCCCCGGGGCTCCT
TCATAGCTGTGGAGTTACGATGATCCAGTGGGGAGCTTGATACCATGGGGCTGGTAGGAAGACCTGCCTGGGCCCAGGGATCCCAACCGGGGCCTTTTG
TATTGATCACAGGTCTCAGAGCCCCCAGCTTCCATAAGACCCAAAACAGACGACACTTCCTCACAGTCCCCTGCGTCTTCTGAGAAGGACAAGCAGTCCA
CTTGGCTGCGGACCTTGGCTGGTTCCTCCAATAAGGTGCTATGTGGGAACCTGTCTGGGGTCTTTGGGGGTGGTGCAAGGCTCTTCTTAGAGCCAACTC
TGTGCCTCTACTCAGCCTCAGGGGCATAAAGTGGCGTGTTTTTCTGTAATCACTCACATAGATTTTCTTGACAG

Tnik

Exon 21
GCTATAAGAAAGCTATAGATGAG

Ptbp1 binding site
TCTCTC/CTCTCT

AGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGTGCAGGCTGGCTGAAACTTAAACTTGGTTTA
AGTTTCTTAGATGCTGTCCTGTGAATGAATGACTCTCAACTACTAGTTTTTGCATCTTAAAGTTGGGGAATTGCTAAGAAATAACAAAGGGGATTTGTATCAT
TCTGGCCTGAGCTTTTCTTTGCTTGTCTGTCTGTATCAGTTTTCTAATAACAATGCCAATTTTGTGTCTAACCTGCTTCTTTTCTTCTGGCTTTTCCCTGACT
GTGGATTCTTCTGAATTGGGTTCCTCTTGCCACAGAGCTATAAGAAAGCTATAGATGAGGTTAGTACTGCCATTTCTTGGTCATGCTTTCATAAGATGTGAAT
ATTGAACTTATTTCCTGTTGTTGACATTCAGAGAGGAAGCCAGTGGTATCATGGGGAAAAGTCCTTTTATACACACCCTTGTTTGGGAGAGGAGGGCTCCT
TCAATAGAATCCAGCCTGAGACCCTCAGATCTACCCATAAAAAGCCCCAGAGTCCTTCACTAAcGCAAAAATATTGCTTTCCTAGTGTCCCAACTGGACAAA
ACACAGACATCAGTATTTTGGTTTCTCCTTCCAGTGCCTTCTAATCACAAACCTGTATTTTCCAGCCTTGCTTGGAGATGGCCCTCAGCAGTTTTACTAACA
CATCCCAAATTTATAGTGTGTAATTTGTGAACAAGGAGTTACTGGTTATTGTTAGATTAATTTTGTGGGACATTAACAACACCATAGGCAGCAACATCAACCTT
AGCTAATGAATCCGGGCTAGTTAAATGATCTATTTCCTTATCTGTGGAGACATTTTCCATTAGAAAAATAGATGGCTGTGTCCCTTGTAGATAGTTTGCTGAG
GACAACTTCCCCATTGCTGTTTGTCAGACCTGCATGAACGCAGCAGAATGCAATGGTTCTGAATCAGCAGGCCTTGCCATGGGTCCCAGATGCATGAACC
GTAAGGCTCGCCATTACAGCTTTGAGGCTGGAGCTCTCCAAAGTATATTTTTGTGAAATTATGTGGAAAAAGCCCTGGCTTCAGGAACCAGCAAGCTATATT
TGAAGCTTGGCTACCTTCAAGGAACGCTGGCTGGGATAAGTCTCATAATCTCAGTAATATGTACAATGGGACTAAATCTCATAATCTGTAAAATGGCAATAAA
AATGTCTGCCCTCCTTTACTTACAAGATTGTTCAGGGTCTTAGGTTTCTGTGTGCAAAGGCATTGTTTAAAGTGGAGAGTGCTTTAGAAAGCCACTGTGATT
GTTCAGGTTTCAGCCACAGGCACAGTACAACTTTTGCAATTAGGGTACCATGATTGTGTGAAGCTGATTCTCATCACAGCTGTGACTACCACACCATCCAC
AGTGAGTCAGAAACTCACACTCCTGGTGAAAGGGTTGCTGTTTATAAAGTAACACTACTCCATATGTCTACAGCCCAGGGACTGGTTATAACCACTCTGGT
CCATTATTTTGCTTTGACCTTACAGTAGTAACAAGGATAGAGGGGCACGCAACTTTGTATCCGTTGCCCCGAGAAGGAAAAGAGAGGAAATTATTTTCTGGT
ACTGGATAGCATAGCTGCCAATTAAGTGGGATTCATATGAACAACTTATGGGTTTGTACAAGTCCAGAAATTAGCATGGAAATGGCTGTTGTGAGAAAAAAG
CTCTCCTGGGTTTCCTCTGGTAAGCCCAGGTGTTCCAGGTTTTTTAAAAATCACTTCATTTATTTTGATGTGTTCTACAACAATCTGATGGAGATGAGAGGG
GCAGCTTCATGCCCAAACCTCTGGCACTGTGGATCAGAGCAAATGCCTCCCAGTGCACTGACACCCCTGGGCATTTACTACCACCGGCCTGGACCACTG
CAACACAGGAAGATGGTCATACCCGACCCAGCGGTTCTTAGCGGTGGTTGCTACCCACATCTTTTACTTAAGAGCTATTCAGCAAATCTCAACTCAGTTTTA
GTTGTTACCCTTGAAAGTGGGAGGCAGCACTGGAGACAATTGTTGTGATACAGAAAAGGGGTGGAGCTAAACATTCTCCAGTTCCCAAAAGGGGTGGAG
CTAAACAGTCACCAATTCCCAAAAGGGGTGGGGCTAAACATCCTCCAGTTCCTAAAAGGGGTGGGGCTAAGCGTCCTGCAACAAAAGGGAATTCCTCAC
AATATAACGCCTCTGGCCCGAAATGGTGAAGGTGCTGGGCTGGGAAATATTGAGCTCAGTTTTAGATCCCATCTTCTTCTGCAATTGTTTTCCTACTTGGAT
GACCCGGAATGAAATGAAAAAGTCCTTTAAACACCTTTTTAAAACTTATTTCTTGTTATTGCTAATTTAGTCATTTAATTTTTCTCATAGTAATAAATCACAAAGG
GTAGCTGTTAAATGGGCATTACTTTCCACTGTACTGTGAAATTTTACCACGCTGCAGTTAGTTAATAAAACTTTTGAAAACAAATAACTTTACTTTCCCATAAC
CGAATGCGTGGCCTGAAGTCTATGTGCAGAAGCAAACATTAGCGGTATGTTTAGAGTTTAATTTTAATCAGGTATAAAAAAAAAAATAATTAAACTGACAATTT
CTAAAAATCACCCACTGATCGGTTGAAACTTAAATAATAATTATTTACTTTGCACCATAGGGGAAAAAAAAACACAGTATTTTGCCATATTTCCCTTTTAGTTA
ATATGTCCTCAAATATTTTTATGCTAAATAGCATTTTTATTTCTCCTCCCCTTTCAATACTTTTTAGCTTCAGGCTTGAGACAACCAAGCAATAAATTACCATAAA
AGGCTCATTATATAGAGGAAATTGGAATTGTCAGAGGATAAAGTGTCCGAAAAAGACCTGAGTCTGGTAGTGGCAATATTGTGTCATGTCTATTTTCTGCAA
CGTTGATATCGCCCATTGTCCTAGTAATGAGCAAATGAAAACCCGAAGTTCAGCTGGCCACAGAGGCCACTGGCAGTGGAGGGTTAATTTTCTTTGGGGG
ATCATGTTTGATCACTCATTACTGCTACCTTGAAATGTTCATCAGTTCCTACTCTCTAAACTGCTACCAATTAAACTGAAATAGATTTGCAATTATTTTGAATGT
TTCAGGAGAAAGCTTTTTAATAACACCAAAATTAAAAAATTCTGATTAAAACCAAAATTATAAAGCAGGTCATAATTTTAAAGTGTTGCTAATTACAGTATTTATG
GAAATGTAGGTCATTTTAGCAAGTGAAACTCTCTTTAACTTATTGGGTAAAGGACTTAACTAAATAATTCTAAATAGATTTTTTTTTTTTTTTTTGTTGTTTAACC
TCTCTTTATCTTATTCTGAAATGTTAGAGATGAGGTAACCATGCCCCAGGGGGAAATGTATCAGTATTTTAAATAAGTCACAGTGGTAGTATTATATTTTACTTAG
ACTTTTTGATAATATAAACAAACTCCTTTAAACCATATTCTCTCTTTAAATTACAATAAAATATAGTTTTTAATAAGTAACATTTTAAATATTAGTTATTTTGTTTGAT
TGTATAACTTTATAAAAATCAAAATATGCAATAAATGTGTCTGATTTGTCCTTTTTGCTAGTTTGGAAGCTTGCTGTGTCCTCTTGCTTTCAGAGTCTTGACAA
ATGTGTGAACAGTTCGTCCCATAGTGCCCATCTAGCGTGTTCTCCATACTCCTTTTGTCTGATAAAGATAAATGTATCAGCAGCAATCAAGAGGAGATGTGC
AGAAGGCTAAACCTAGATACTGGCCTTTCCTGGTTTGGGTGCATTGCCTAAGAAGCTAGAAGTATATTTGTATAAAATTCTCTGTGTGAGGAGGCTCTCCCC


A
siNT
siFmr1
300
250
SETD2
100
FMRP
70
LaminB1
15
H3K36me3
15
H3
B
N2a
siNT
siFmr1
+ Ex 5
– Ex 5
Ex 9
Mbnl2 Exon 5
Inclusion/Skipping
(Relative band intensity)
1.5
1.0
0.5
0.0
*
siNT siFmr1
HC
WT
KO
+ Ex 5
– Ex 5
Ex 9
Mbnl2 Exon 5
Inclusion/Skipping
(Relative band intensity)
1.5
1.0
0.5
0.0
*
WT
KO


A
siNT
siFmr1
siMbnl1
siFmr1+
nMBNL1
siMbnl1+
cMBNL1
40
70
35
MBNL1
FMRP
GAPDH


A
siFmr1+nMBNL1
siMbnl1+cMBNL1
Delta PSI
1.5
1.0
0.5
0.0
-0.5
-1.0
-1.5
SE
MXE
A3SS
A5SS
RI
B
Mbnl1 ex5
PSI
1.5
1.0
0.5
0.0
siNT
siFmr1
siMbnl1
siFmr1+nMBNL1
siMbnl1+cMBNL1
C
siFmr1 SE Exons
siMbnl1 SE Exons
2021
1393
2602


A
siNT vs. siFmr1
15
10
5
0
−Log10 P adj
-2
0
2
Log2 fold change
Hnrnpa1
Nova1
Gcfc2
Rbm12
Atxn7
Cdk13
Gpkow
Rest
Slc38a2
Rnpc3
Cdk12
Fam50a
Smndc1
Ythdc1
Snrpn
Sart1
Elavl4
Taf15
Cirbp
Hnrnph3
Wbp11
Prpf40b
Rbm24
Arl6ip4
B
siNT vs. siFmr1
15
10
5
0
−Log10 P
-1.0
-0.5
0.0
0.5
1.0
delta PSI
Srsf7
Prpf39
Prdx6
Lsm2
Sf1
Fxr1
U2af2
Usb1
U2af1
Dazap1
Snrnp70
Tmbim6
Akap17b
Txnl4a
Nup98
Tia1